<!DOCTYPE html>
<html lang="en" class="scroll-smooth">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>Pharmacology Test - Brain And Scalpel</title>
    <link rel="preload" href="assets/background.jpg" as="image">
    <script src="https://cdn.tailwindcss.com"></script>
    <!-- HLS.js for M3U8 support -->
    <script src="https://cdn.jsdelivr.net/npm/hls.js@latest"></script>
    <style>
        
/* Liquid Glass Morphism Universal Theme - Enhanced & Mobile-First */
:root {
  --glass-bg: rgba(0, 0, 0, 0.6);
  --glass-bg-light: rgba(255, 255, 255, 0.1);
  --glass-bg-medium: rgba(255, 255, 255, 0.15);
  --glass-bg-heavy: rgba(255, 255, 255, 0.2);
  --glass-border: rgba(255, 255, 255, 0.2);
  --glass-border-light: rgba(255, 255, 255, 0.1);
  --text-primary: rgba(255, 255, 255, 0.95);
  --text-secondary: rgba(255, 255, 255, 0.7);
  --text-tertiary: rgba(255, 255, 255, 0.5);
  --accent-blue: #60a5fa;
  --accent-purple: #a855f7;
  --accent-green: #34d399;
  --accent-orange: #fb923c;
  --accent-red: #f87171;
  --accent-yellow: #fbbf24;
}

* {
  margin: 0;
  padding: 0;
  box-sizing: border-box;
}

html {
  scroll-behavior: smooth;
}

body {
  margin: 0;
  min-height: 100vh;
  font-family: system-ui, -apple-system, BlinkMacSystemFont, 'Segoe UI', sans-serif;
  position: relative;
  overflow-x: hidden;
  color: var(--text-primary);
  background-color: #000;
}

/* iOS Background Fix */
body::before {
  content: '';
  position: fixed;
  top: 0;
  left: 0;
  height: 100vh;
  width: 100vw;
  z-index: -2;
  background: url("assets/background.jpg") center center / cover no-repeat;
}

body::after {
  content: "";
  position: fixed;
  inset: 0;
  background: rgba(0, 0, 0, 0.4);
  backdrop-filter: blur(10px);
  -webkit-backdrop-filter: blur(10px);
  z-index: -1;
}

/* Glass morphism components */
.glass {
  background: var(--glass-bg);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-light {
  background: var(--glass-bg-light);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid var(--glass-border-light);
  border-radius: 12px;
}

.glass-medium {
  background: var(--glass-bg-medium);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid var(--glass-border);
  border-radius: 16px;
}

.glass-heavy {
  background: var(--glass-bg-heavy);
  backdrop-filter: blur(25px);
  -webkit-backdrop-filter: blur(25px);
  border: 1px solid var(--glass-border);
  border-radius: 20px;
}

.glass-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.glass-card:hover {
  transform: translateY(-8px);
  background: rgba(255, 255, 255, 0.12);
  border-color: rgba(255, 255, 255, 0.25);
  box-shadow: 0 20px 60px rgba(0, 0, 0, 0.4);
}

.glass-button {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.8), rgba(168, 85, 247, 0.8));
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: white;
  font-weight: 600;
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  box-shadow: 0 4px 20px rgba(96, 165, 250, 0.3);
  cursor: pointer;
  border: none;
}

.glass-button:hover {
  transform: translateY(-2px);
  box-shadow: 0 8px 30px rgba(96, 165, 250, 0.4);
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.9), rgba(168, 85, 247, 0.9));
}

.glass-button:disabled {
  opacity: 0.5;
  cursor: not-allowed;
  transform: none;
}

.glass-input {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(15px);
  -webkit-backdrop-filter: blur(15px);
  border: 1px solid rgba(255, 255, 255, 0.2);
  border-radius: 12px;
  color: var(--text-primary);
  transition: all 0.3s ease;
}

.glass-input:focus {
  outline: none;
  border-color: var(--accent-blue);
  background: rgba(255, 255, 255, 0.12);
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.3);
}

.glass-input::placeholder {
  color: var(--text-tertiary);
}

/* Performance analysis styles */
.performance-card {
  background: rgba(255, 255, 255, 0.08);
  backdrop-filter: blur(20px);
  -webkit-backdrop-filter: blur(20px);
  border: 1px solid rgba(255, 255, 255, 0.15);
  border-radius: 20px;
  box-shadow: 0 8px 32px rgba(0, 0, 0, 0.3);
}

.score-circle {
  position: relative;
  width: 150px;
  height: 150px;
  margin: 0 auto;
}

.score-circle svg {
  transform: rotate(-90deg);
}

.score-circle .circle-bg {
  fill: none;
  stroke: rgba(255, 255, 255, 0.1);
  stroke-width: 8;
}

.score-circle .circle-progress {
  fill: none;
  stroke-width: 8;
  stroke-linecap: round;
  transition: stroke-dasharray 2s cubic-bezier(0.4, 0, 0.2, 1);
}

.score-text {
  position: absolute;
  top: 50%;
  left: 50%;
  transform: translate(-50%, -50%);
  text-align: center;
}

/* Review question styles */
.review-question {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.1);
  border-radius: 16px;
  padding: 20px;
  margin-bottom: 20px;
}

.review-question.correct {
  border-left: 4px solid #22c55e;
}

.review-question.incorrect {
  border-left: 4px solid #ef4444;
}

.review-question.not-attempted {
  border-left: 4px solid #6b7280;
}

/* Gradient backgrounds for accents */
.gradient-blue {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
}

.gradient-purple {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
}

.gradient-green {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
}

.gradient-orange {
  background: linear-gradient(135deg, var(--accent-orange), #f97316);
}

.gradient-red {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
}

.gradient-yellow {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
}

/* Navigation button styles */
.nav-btn-not-attempted {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  color: rgba(255, 255, 255, 0.7);
}

.nav-btn-current {
  background: linear-gradient(135deg, var(--accent-blue), #3b82f6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
  box-shadow: 0 0 20px rgba(96, 165, 250, 0.4);
}

.nav-btn-correct {
  background: linear-gradient(135deg, var(--accent-green), #10b981);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-incorrect {
  background: linear-gradient(135deg, var(--accent-red), #ef4444);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-bookmarked {
  background: linear-gradient(135deg, var(--accent-yellow), #f59e0b);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-marked-review {
  background: linear-gradient(135deg, var(--accent-purple), #8b5cf6);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

.nav-btn-answered {
  background: linear-gradient(135deg, #6b7280, #4b5563);
  border: 1px solid rgba(255, 255, 255, 0.3);
  color: white;
}

/* Option button styles - REVISED FOR INLINE FEEDBACK */
.option-button {
  background: rgba(255, 255, 255, 0.05);
  border: 1px solid rgba(255, 255, 255, 0.15);
  transition: all 0.3s cubic-bezier(0.4, 0, 0.2, 1);
  position: relative;
  overflow: hidden;
  width: 100%;
  text-align: left;
  padding: 1rem;
  border-radius: 12px;
  color: var(--text-primary);
  cursor: pointer;
  display: flex;
  align-items: center;
  gap: 1rem;
  font-size: 1rem;
}

.option-button:hover {
  background: rgba(255, 255, 255, 0.1);
  border-color: rgba(96, 165, 250, 0.5);
  transform: translateX(8px);
}

.option-button.selected {
  background: linear-gradient(135deg, rgba(96, 165, 250, 0.3), rgba(59, 130, 246, 0.3));
  border-color: var(--accent-blue);
  transform: translateX(8px);
}

#optionsContainer.answered .option-button:hover {
    transform: translateX(0); /* Disable hover effect after answering */
}

#optionsContainer.answered .option-button {
    cursor: not-allowed;
    pointer-events: none;
}

#optionsContainer.answered .option-button:not(.correct):not(.incorrect) {
    opacity: 0.5;
}

.option-button.correct {
    background: linear-gradient(135deg, #22c55e, #16a34a);
    border-color: #22c55e;
    color: white;
    transform: translateX(0);
}

.option-button.incorrect {
    background: linear-gradient(135deg, #ef4444, #dc2626);
    border-color: #ef4444;
    color: white;
    transform: translateX(0);
}

.option-letter {
  background: rgba(255, 255, 255, 0.1);
  border: 1px solid rgba(255, 255, 255, 0.2);
  transition: all 0.3s ease;
  width: 2.5rem;
  height: 2.5rem;
  border-radius: 50%;
  display: flex;
  align-items: center;
  justify-content: center;
  font-weight: bold;
  color: var(--text-primary);
  flex-shrink: 0;
}

.option-button.selected .option-letter {
  background: var(--accent-blue);
  border-color: var(--accent-blue);
  color: white;
}

.option-button.correct .option-letter, .option-button.incorrect .option-letter {
    background: rgba(255, 255, 255, 0.2);
    border-color: rgba(255, 255, 255, 0.3);
}

.option-text {
  flex: 1;
  font-size: 1rem;
  line-height: 1.5;
}

/* Stats bar responsive grid */
.stats-grid {
  display: grid;
  grid-template-columns: repeat(5, 1fr);
  gap: 1rem;
  align-items: center;
  justify-items: center;
}

@media (max-width: 768px) {
  .stats-grid {
    grid-template-columns: repeat(3, 1fr);
    gap: 0.5rem;
  }
 
  .stats-grid > div:nth-child(4),
  .stats-grid > div:nth-child(5) {
    grid-column: span 1;
  }
}

@media (max-width: 480px) {
  .stats-grid {
    grid-template-columns: repeat(2, 1fr);
  }
 
  .stats-grid > div:last-child {
    grid-column: span 2;
    justify-self: center;
  }
}

/* Animations */
@keyframes float {
  0%, 100% { transform: translateY(0px); }
  50% { transform: translateY(-20px); }
}

@keyframes pulse-glow {
  0%, 100% { box-shadow: 0 0 20px rgba(96, 165, 250, 0.3); }
  50% { box-shadow: 0 0 40px rgba(96, 165, 250, 0.6); }
}

@keyframes checkmark {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(180deg); }
  100% { transform: scale(1) rotate(360deg); }
}

@keyframes cross {
  0% { transform: scale(0) rotate(0deg); }
  50% { transform: scale(0.8) rotate(90deg); }
  100% { transform: scale(1) rotate(180deg); }
}

.animate-float {
  animation: float 6s ease-in-out infinite;
}

.animate-pulse-glow {
  animation: pulse-glow 2s ease-in-out infinite;
}

.animate-checkmark {
  animation: checkmark 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

.animate-cross {
  animation: cross 0.6s cubic-bezier(0.4, 0, 0.2, 1);
}

/* Custom scrollbar */
::-webkit-scrollbar {
  width: 8px;
}

::-webkit-scrollbar-track {
  background: rgba(255, 255, 255, 0.05);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb {
  background: rgba(255, 255, 255, 0.2);
  border-radius: 4px;
}

::-webkit-scrollbar-thumb:hover {
  background: rgba(255, 255, 255, 0.3);
}

/* --- MOBILE RESPONSIVE STYLES --- */
.quiz-container {
    display: flex;
    flex-direction: column;
    gap: 1.5rem;
}

#mobile-nav-toggle {
    display: none; /* Hidden on desktop */
}

@media (min-width: 1024px) {
    .quiz-container {
        flex-direction: row;
        gap: 2rem;
    }
}

@media (max-width: 1023px) {
    .quiz-sidebar {
        position: fixed;
        top: 0;
        left: 0;
        width: 300px;
        height: 100%;
        z-index: 100;
        transform: translateX(-100%);
        transition: transform 0.3s ease-in-out;
        box-shadow: 10px 0px 30px rgba(0,0,0,0.5);
    }
    .quiz-sidebar.open {
        transform: translateX(0);
    }
    #mobile-nav-toggle {
        display: flex;
        position: fixed;
        bottom: 20px;
        left: 20px;
        z-index: 50;
    }
    .quiz-main-content {
        width: 100%;
    }
}

@media (max-width: 768px) {
    .glass-card, .glass {
        border-radius: 16px;
    }
    h1 { font-size: 2.5rem; }
    #questionText { font-size: 1.125rem; }
    .controls-container {
        flex-direction: column;
        gap: 1rem;
    }
    .controls-container button {
        width: 100%;
    }
}

    </style>
</head>
<body>
    <!-- Mode Selection Modal -->
    <div id="modeModal" class="fixed inset-0 bg-black bg-opacity-70 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-md w-full mx-4 shadow-2xl">
            <h2 class="text-2xl font-bold text-white mb-6 text-center">Choose Study Mode</h2>
            
            <div class="space-y-4">
                <button onclick="selectMode('study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Study Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Interactive learning with immediate feedback</p>
                        </div>
                        <div class="gradient-blue w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 12l2 2 4-4m6 2a9 9 0 11-18 0 9 9 0 0118 0z"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('test')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Test Mode</h3>
                            <p class="text-sm text-white text-opacity-70">Practice test with performance analysis at end</p>
                        </div>
                        <div class="gradient-purple w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path d="M9 2a1 1 0 000 2h2a1 1 0 100-2H9z"></path>
                                <path fill-rule="evenodd" d="M4 5a2 2 0 012-2v1a1 1 0 001 1h6a1 1 0 001-1V3a2 2 0 012 2v6a2 2 0 01-2 2H6a2 2 0 01-2-2V5zm3 4a1 1 0 000 2h.01a1 1 0 100-2H7zm3 0a1 1 0 000 2h3a1 1 0 100-2h-3z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_study')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Study</h3>
                            <p class="text-sm text-white text-opacity-70">Study with time pressure and immediate feedback</p>
                        </div>
                        <div class="gradient-green w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M10 18a8 8 0 100-16 8 8 0 000 16zm1-12a1 1 0 10-2 0v4a1 1 0 00.293.707l2.828 2.829a1 1 0 101.415-1.415L11 9.586V6z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
                
                <button onclick="selectMode('timed_exam')" class="w-full text-left p-4 glass-light hover:bg-white hover:bg-opacity-10 transition-all duration-300 text-white">
                    <div class="flex items-center justify-between">
                        <div>
                            <h3 class="font-semibold">Timed Exam</h3>
                            <p class="text-sm text-white text-opacity-70">Real exam simulation with strict timing</p>
                        </div>
                        <div class="gradient-red w-10 h-10 rounded-lg flex items-center justify-center">
                            <svg class="w-5 h-5 text-white" fill="currentColor" viewBox="0 0 20 20">
                                <path fill-rule="evenodd" d="M12.395 2.553a1 1 0 00-1.45-.385c-.345.23-.614.558-.822.88-.214.33-.403.713-.57 1.116-.334.804-.614 1.768-.84 2.734a31.365 31.365 0 00-.613 3.58 2.64 2.64 0 01-.945-1.067c-.328-.68-.398-1.534-.398-2.654A1 1 0 005.05 6.05 6.981 6.981 0 003 11a7 7 0 1011.95-4.95c-.592-.591-.98-.985-1.348-1.467-.363-.476-.724-1.063-1.207-2.03z" clip-rule="evenodd"></path>
                            </svg>
                        </div>
                    </div>
                </button>
            </div>
        </div>
    </div>

    <!-- Performance Analysis Modal -->
    <div id="performanceModal" class="hidden fixed inset-0 bg-black bg-opacity-80 flex items-center justify-center z-50 backdrop-blur-sm">
        <div class="glass-heavy p-8 max-w-4xl w-full mx-4 shadow-2xl max-h-[90vh] overflow-y-auto">
            <div class="flex items-center justify-between mb-8">
                <h2 class="text-3xl font-bold text-white">Performance Analysis</h2>
                <button onclick="closePerformanceModal()" class="glass-light p-2 rounded-lg text-white hover:bg-white hover:bg-opacity-20">
                    <svg class="w-6 h-6" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M4.293 4.293a1 1 0 011.414 0L10 8.586l4.293-4.293a1 1 0 111.414 1.414L11.414 10l4.293 4.293a1 1 0 01-1.414 1.414L10 11.414l-4.293 4.293a1 1 0 01-1.414-1.414L8.586 10 4.293 5.707a1 1 0 010-1.414z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
            
            <!-- Score Overview -->
            <div class="grid grid-cols-1 md:grid-cols-3 gap-6 mb-8">
                <div class="performance-card p-6 text-center">
                    <div class="score-circle mb-4">
                        <svg width="150" height="150" class="mx-auto">
                            <circle class="circle-bg" cx="75" cy="75" r="65"></circle>
                            <circle id="scoreCircle" class="circle-progress" cx="75" cy="75" r="65" stroke="#22c55e" stroke-dasharray="0 408"></circle>
                        </svg>
                        <div class="score-text">
                            <div class="text-3xl font-bold text-white" id="accuracyScore">0%</div>
                            <div class="text-sm text-white text-opacity-70">Accuracy</div>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Results Summary</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Questions:</span>
                            <span class="text-white font-semibold" id="totalQuestionsResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-green-400">Correct:</span>
                            <span class="text-green-400 font-semibold" id="correctResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-red-400">Incorrect:</span>
                            <span class="text-red-400 font-semibold" id="incorrectResult">0</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-gray-400">Not Attempted:</span>
                            <span class="text-gray-400 font-semibold" id="notAttemptedResult">0</span>
                        </div>
                    </div>
                </div>
                
                <div class="performance-card p-6">
                    <h3 class="text-lg font-bold text-white mb-4 text-center">Time Analysis</h3>
                    <div class="space-y-3">
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Total Time:</span>
                            <span class="text-white font-semibold" id="totalTimeResult">0:00</span>
                        </div>
                        <div class="flex justify-between items-center">
                            <span class="text-white text-opacity-70">Avg per Question:</span>
                            <span class="text-white font-semibold" id="avgTimeResult">0:00</span>
                        </div>
                    </div>
                </div>
            </div>
            
            <!-- Action Buttons -->
            <div class="flex justify-center space-x-4 mb-8">
                <button onclick="reviewQuestions()" class="glass-button px-8 py-3 text-lg">
                    Review All Questions
                </button>
                <button onclick="retakeQuiz()" class="glass-light px-8 py-3 text-lg text-white hover:bg-white hover:bg-opacity-20">
                    Retake Quiz
                </button>
            </div>
            
            <!-- Question Review Section -->
            <div id="questionReviewSection" class="hidden">
                <h3 class="text-2xl font-bold text-white mb-6">Question Review</h3>
                <div id="reviewQuestionsContainer">
                    <!-- Review questions will be populated here -->
                </div>
            </div>
        </div>
    </div>

    <!-- Header -->
    <header class="glass sticky top-0 z-40 mb-6">
        <div class="container mx-auto px-6 py-4">
            <div class="flex items-center justify-between">
                <div class="flex items-center space-x-4">
                    <button onclick="goBack()" class="glass-light px-4 py-2 text-white hover:bg-white hover:bg-opacity-20 transition-all duration-300 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M9.707 16.707a1 1 0 01-1.414 0l-6-6a1 1 0 010-1.414l6-6a1 1 0 011.414 1.414L5.414 9H17a1 1 0 110 2H5.414l4.293 4.293a1 1 0 010 1.414z" clip-rule="evenodd"></path>
                        </svg>
                        Back
                    </button>
                    <div id="quizHierarchy" class="text-sm text-white text-opacity-60">
                        Marrow / NEET PG Test Series Subject Wise / Year 2024 - 25
                    </div>
                </div>
                
                <div class="flex items-center space-x-4">
                    <div class="glass-light px-3 py-1 text-sm text-white">
                        Question <span id="currentQuestion">1</span> of <span id="totalQuestions">50</span>
                    </div>
                    
                    <!-- Timer -->
                    <div id="timerContainer" class="hidden gradient-red px-3 py-1 text-sm text-white font-bold animate-pulse-glow">
                        <span id="timeDisplay">2:00</span>
                    </div>
                </div>
            </div>
        </div>
    </header>

    <!-- Progress Bar -->
    <div class="w-full h-1 bg-black bg-opacity-30 mb-6">
        <div id="progressBar" class="h-1 gradient-blue transition-all duration-500 ease-out" style="width: 0%"></div>
    </div>

    <!-- Stats Bar - Show only in study modes -->
    <div id="statsBar" class="glass-light mb-8">
        <div class="container mx-auto px-6 py-4">
            <div class="stats-grid">
                <div class="text-center">
                    <div class="text-lg font-bold text-green-400" id="correctCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Correct</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-red-400" id="incorrectCount">0</div>
                    <div class="text-xs text-white text-opacity-60">Incorrect</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-blue-400" id="totalAttempted">0</div>
                    <div class="text-xs text-white text-opacity-60">Attempted</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-purple-400" id="accuracy">0%</div>
                    <div class="text-xs text-white text-opacity-60">Accuracy</div>
                </div>
                <div class="text-center">
                    <div class="text-lg font-bold text-orange-400" id="timeSpent">0:00</div>
                    <div class="text-xs text-white text-opacity-60">Time</div>
                </div>
            </div>
        </div>
    </div>

    <div class="quiz-container container mx-auto px-6">
        <!-- Question Navigation Sidebar -->
        <div id="quizSidebar" class="quiz-sidebar glass p-6 h-fit lg:sticky top-24">
            <h3 class="text-lg font-bold text-white mb-4">Question Navigator</h3>
            <div id="questionNav" class="grid grid-cols-5 gap-2 mb-6">
                <!-- Question numbers will be populated here -->
            </div>
            
            <div class="space-y-3 text-xs">
                <h4 class="text-sm font-medium text-white text-opacity-80 mb-3">Legend</h4>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-not-attempted rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Not Attempted</span>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-current rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Current</span>
                </div>
                <div id="studyModeLegend" class="space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-correct rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Correct</span>
                    </div>
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-incorrect rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Incorrect</span>
                    </div>
                </div>
                <div id="testModeLegend" class="hidden space-y-2">
                    <div class="flex items-center">
                        <div class="w-6 h-6 nav-btn-answered rounded mr-2"></div>
                        <span class="text-white text-opacity-60">Answered</span>
                    </div>
                </div>
                <div class="flex items-center">
                    <div class="w-6 h-6 nav-btn-bookmarked rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Bookmarked</span>
                </div>
                <div id="testModeReviewLegend" class="hidden items-center">
                    <div class="w-6 h-6 nav-btn-marked-review rounded mr-2"></div>
                    <span class="text-white text-opacity-60">Marked for Review</span>
                </div>
            </div>
            
            <!-- Submit Quiz Button for test modes -->
            <div id="submitSection" class="hidden mt-6">
                <button onclick="submitQuiz()" class="glass-button w-full py-3 text-lg font-bold">
                    Submit Quiz
                </button>
            </div>
        </div>

        <!-- Main Quiz Interface -->
        <div class="quiz-main-content flex-1 max-w-4xl">
            <div class="glass-card p-4 md:p-8 lg:p-12 mb-8 relative">
                <!-- Question Text -->
                <div id="questionText" class="text-xl lg:text-2xl leading-relaxed text-white mb-8">
                    Loading question...
                </div>

                <!-- Question Media -->
                <div id="questionMedia" class="mb-8"></div>

                <!-- Options -->
                <div id="optionsContainer" class="space-y-3 mb-8">
                    <!-- Options will be inserted here -->
                </div>

                <!-- Solution Display (only for study modes) -->
                <div id="solutionContainer" class="hidden glass-light p-6 border-l-4 border-green-400">
                    <h3 class="text-lg font-bold text-green-400 mb-3 flex items-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                            <path fill-rule="evenodd" d="M18 10a8 8 0 11-16 0 8 8 0 0116 0zm-7-4a1 1 0 11-2 0 1 1 0 012 0zM9 9a1 1 0 000 2v3a1 1 0 001 1h1a1 1 0 100-2v-3a1 1 0 00-1-1H9z" clip-rule="evenodd"></path>
                        </svg>
                        Explanation
                    </h3>
                    <div id="solutionText" class="text-white text-opacity-90 leading-relaxed mb-4"></div>
                    <div id="solutionAudio" class="space-y-2 mt-4"></div>
                    <div id="solutionImages" class="space-y-4 mt-4"></div>
                    <div id="solutionVideo" class="hidden mt-4">
                        <video id="explanationVideoPlayer" class="w-full rounded-lg" controls>
                            Your browser does not support the video tag.
                        </video>
                    </div>
                </div>
            </div>

            <!-- Controls -->
            <div class="controls-container flex justify-between items-center mb-8">
                <button onclick="previousQuestion()" id="prevBtn" class="glass-button px-6 py-3 flex items-center justify-center disabled:opacity-50 disabled:cursor-not-allowed">
                    <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M12.707 5.293a1 1 0 010 1.414L9.414 10l3.293 3.293a1 1 0 01-1.414 1.414l-4-4a1 1 0 010-1.414l4-4a1 1 0 011.414 0z" clip-rule="evenodd"></path>
                    </svg>
                    Previous
                </button>
                
                <div class="flex justify-center flex-grow">
                    <button onclick="toggleBookmark()" id="bookmarkBtn" class="glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" id="bookmarkIcon" fill="currentColor" viewBox="0 0 20 20">
                            <path d="M5 4a2 2 0 012-2h6a2 2 0 012 2v14l-5-2.5L5 18V4z"></path>
                        </svg>
                        <span id="bookmarkText">Bookmark</span>
                    </button>
                    
                    <button onclick="toggleMarkForReview()" id="markReviewBtn" class="hidden glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center justify-center">
                        <svg class="w-5 h-5 mr-2" fill="currentColor" viewBox="0 0 20 20">
                           <path fill-rule="evenodd" d="M5 2a2 2 0 00-2 2v12a2 2 0 002 2h10a2 2 0 002-2V4a2 2 0 00-2-2H5zm0 2h10v12H5V4z" clip-rule="evenodd" />
                           <path d="M12.586 6.586a2 2 0 10-2.828 2.828l-3 3a2 2 0 102.828-2.828l3-3z" />
                        </svg>
                        <span id="markReviewText">Mark for Review</span>
                    </button>
                </div>
                
                <button onclick="nextQuestion()" class="glass-button px-6 py-3 flex items-center justify-center">
                    Next
                    <svg class="w-5 h-5 ml-2" fill="currentColor" viewBox="0 0 20 20">
                        <path fill-rule="evenodd" d="M7.293 14.707a1 1 0 010-1.414L10.586 10 7.293 6.707a1 1 0 011.414-1.414l4 4a1 1 0 010 1.414l-4 4a1 1 0 01-1.414 0z" clip-rule="evenodd"></path>
                    </svg>
                </button>
            </div>
        </div>
    </div>

     <!-- Mobile Nav Toggle -->
    <button id="mobile-nav-toggle" onclick="toggleSidebar()" class="glass-button w-14 h-14 rounded-full items-center justify-center">
        <svg class="w-6 h-6 text-white" fill="none" stroke="currentColor" viewBox="0 0 24 24"><path stroke-linecap="round" stroke-linejoin="round" stroke-width="2" d="M4 6h16M4 12h16M4 18h16"></path></svg>
    </button>


    <script>
        let questionsData = [
  {
    "text": "Match the following chemotherapeutic agents with their adverse effects.",
    "choices": [
      {
        "id": 1,
        "text": "1-a, 2-c, 3-d, 4-b"
      },
      {
        "id": 2,
        "text": "1-c, 2-d, 3-a, 4-b"
      },
      {
        "id": 3,
        "text": "1-d, 2-b, 3-a, 4-c"
      },
      {
        "id": 4,
        "text": "1-d, 2-a, 3-b, 4-c"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The correct match is;</p>\n<table style=\"width: 282px;\">\n<tbody>\n<tr style=\"height: 18px;\">\n<td style=\"width: 147.295px; height: 18px; text-align: center;\"><strong>Drugs</strong></td>\n<td style=\"width: 140.705px; height: 18px; text-align: center;\"><strong>Adverse effects</strong></td>\n</tr>\n<tr style=\"height: 35.3239px;\">\n<td style=\"width: 147.295px; height: 35.3239px;\">1. Bleomycin</td>\n<td style=\"width: 140.705px; height: 35.3239px;\">\n<p>c. Pulmonary fibrosis</p>\n</td>\n</tr>\n<tr style=\"height: 34px;\">\n<td style=\"width: 147.295px; height: 34px;\">2. Doxorubicin</td>\n<td style=\"width: 140.705px; height: 34px;\">\n<p>d. Cardiotoxicity</p>\n</td>\n</tr>\n<tr style=\"height: 36px;\">\n<td style=\"width: 147.295px; height: 36px;\">3. Vincristine</td>\n<td style=\"width: 140.705px; height: 36px;\">\n<p>a. Peripheral neuropathy</p>\n</td>\n</tr>\n<tr style=\"height: 42px;\">\n<td style=\"width: 147.295px; height: 42px;\">4. Capecitabine</td>\n<td style=\"width: 140.705px; height: 42px;\">\n<p>b. Hand-foot syndrome.</p>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Bleomycin\u00a0</strong>is an anticancer antibiotic used for the treatment of squamous cell cancer and Hodgkin lymphoma. It chelates copper or iron and produces superoxide ions that damage DNA. Side effects are mucocutaneous toxicity and\u00a0<strong>pulmonary fibrosis.</strong></p>\n<p><strong>Doxorubicin</strong> is an\u00a0<strong>anthracycline</strong>\u00a0that is widely used in clinical practice as a chemotherapeutic agent. It is most commonly used as a part of regimens with other agents like cyclophosphamide, cisplatin, and 5-FU in several malignancies including:\u00a0</p>\n<ul>\n<li>Breast cancer</li>\n<li>Endometrial cancer</li>\n<li>Ovarian cancer</li>\n<li>Soft-tissue sarcoma</li>\n<li>Neuroblastoma</li>\n<li>Ewing's sarcoma</li>\n<li>Rhabdomyosarcoma</li>\n<li>ALL</li>\n<li>Multiple myeloma</li>\n<li>Hodgkin's and Non-Hodgkin's lymphoma</li>\n</ul>\n<p><strong>Cardiotoxicity</strong>\u00a0is a known side-effect of doxorubicin. Therefore, careful monitoring is required for doxorubicin. Specifically, doxorubicin requires dose adjustment during or after radiotherapy in order to prevent radiation toxicity.</p>\n<p><strong>Vincristine</strong>\u00a0is a vinca alkaloid that acts during the\u00a0<strong>M phase</strong>\u00a0of the cell cycle. It causes microtubule disruptions, thereby preventing cellular replication.\u00a0Side effects are <strong>neuropathy</strong>\u00a0and SIADH.</p>\n<p><strong>Capecitabine</strong>\u00a0is a\u00a0<strong>pyrimidine analog</strong>\u00a0that is classified as an\u00a0<strong>antimetabolite agent</strong>. Side effects are diarrhea, <strong>hand-foot syndrome</strong>, and myelosuppression.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 26-year-old man with a history of severe psoriasis has been planned to be initiated on a monoclonal antibody that targets the IL-17A cytokine. Which of the following drugs is he most likely to be prescribed?",
    "choices": [
      {
        "id": 1,
        "text": "Secukinumab"
      },
      {
        "id": 2,
        "text": "Ustekinumab"
      },
      {
        "id": 3,
        "text": "Brodalumab"
      },
      {
        "id": 4,
        "text": "Adalimumab"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Secukinumab</strong> is a <strong>monoclonal antibody</strong> that targets the<strong> IL-17A cytokine</strong>. It is approved for the treatment of <strong>moderate to severe plaque psoriasis</strong>, psoriatic arthritis, and ankylosing spondylitis. Secukinumab is administered as a <strong>subcutaneous</strong> injection every <strong>4 or 12 weeks</strong>.</p>\n<p><strong>Newer</strong> drugs approved for the treatment of <strong>psoriatic</strong> <strong>arthritis</strong> include:</p>\n<table style=\"border-collapse: collapse; width: 48.3747%; height: 255.955px;\" border=\"1\">\n<tbody>\n<tr style=\"height: 22.3958px;\">\n<td style=\"width: 50.0423%; text-align: center; height: 22.3958px;\">Class of drug</td>\n<td style=\"width: 50.0423%; text-align: center; height: 22.3958px;\">Drugs</td>\n</tr>\n<tr style=\"height: 143.976px;\">\n<td style=\"width: 50.0423%; height: 143.976px; text-align: center;\">Anti-TNF \u03b1</td>\n<td style=\"width: 50.0423%; height: 143.976px;\">\u00a0<strong>Infliximab</strong> (only <strong>IV</strong> drug, rest all are s/c)<br />\n<ul>\n<li>Etanercept\u00a0</li>\n<li>Adalimumab\u00a0</li>\n<li>Golimumab</li>\n<li>Certolizumab</li>\n</ul>\n</td>\n</tr>\n<tr style=\"height: 22.3958px;\">\n<td style=\"width: 50.0423%; height: 22.3958px; text-align: center;\">Anti-IL-17</td>\n<td style=\"width: 50.0423%; height: 22.3958px;\">Secukinumab</td>\n</tr>\n<tr style=\"height: 22.3958px;\">\n<td style=\"width: 50.0423%; height: 22.3958px; text-align: center;\">Anti-IL-23 and IL-12</td>\n<td style=\"width: 50.0423%; height: 22.3958px;\">Ustekinumab</td>\n</tr>\n</tbody>\n</table>\n<p>Other options:</p>\n<p>Option B: <strong>Ustekinumab</strong> is a fully human IgG1 \u00a0<strong>monoclonal antibody</strong> against the <strong>p40 subunit</strong> that is common to both <strong>IL\u201012 and IL\u201023</strong>. Ustekinumab is indicated for <strong>severe plaque psoriasis</strong>, psoriatic arthritis, and Crohn's disease. Dizziness, sore throat and joint pain are the most common side effects associated with Ustekinumab. Ustekinumab is administered as a subcutaneous injection every 12 weeks.</p>\n<p>Option C: <strong>Brodalumab</strong> is a <strong>monoclonal antibody </strong>that targets the<strong> IL-17RA receptor</strong>. It is approved for the treatment of <strong>moderate to severe plaque psoriasis</strong>. Brodalumab is administered as a subcutaneous injection every 2 weeks. It leads to black tarry stools, lethargy, and joint pain as the most common adverse effects.</p>\n<p>Option D: \u00a0<strong>Adalimumab</strong> is an <strong>anti-TNF-\ud835\udec2 antibody</strong>. It is approved for the use of rheumatoid arthritis, juvenile idiopathic arthritis, <strong>plaque psoriasis</strong>, Crohn's disease, and ulcerative colitis. \u00a0</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A young patient presented with symptoms of bronchial asthma and cromolyn sodium was prescribed. It should be administered by which of the following routes?",
    "choices": [
      {
        "id": 1,
        "text": "Inhalation"
      },
      {
        "id": 2,
        "text": "Oral"
      },
      {
        "id": 3,
        "text": "IV"
      },
      {
        "id": 4,
        "text": "IM"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Cromolyn</strong> <strong>sodium</strong> (Sodium cromoglycate) is administered through the <strong>inhalation route</strong><strong>\u00a0</strong>as an <strong>aerosol,</strong> through a metered-dose inhaler (MDI) in bronchial asthma.<br /><br />Sodium cromoglycate is a <strong>mast cell stabilizer,</strong> which inhibits the degranulation of mast cells and restricts the release of inflammatory cytokines. It <strong>prevents bronchoconstriction</strong> but does not act as a direct bronchodilator and hence cannot be used once bronchoconstriction is established or during an asthmatic attack.\u00a0</p>\n<p>It is not absorbed orally. It is administered through the inhalation route for the treatment of bronchial asthma. It can also be used in the treatment of allergic conjunctivitis as a topical application.</p>\n<div class=\"page\" title=\"Page 266\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>The therapeutic benefit develops slowly over 2-4 weeks and lasts 1- 2 weeks after discontinuation of the drug. Its use has declined due to the widespread usage of inhaled corticosteroids.</p>\n<p><strong>Drugs used in the treatment of bronchial asthma</strong></p>\n<p><strong>Bronchodilators</strong></p>\n<ul>\n<li>Beta-2 sympathomimetics: Salmeterol, Formoterol</li>\n<li>Methylxanthines: Theophylline, Aminophylline</li>\n<li>Anticholinergics: Ipratropium bromide, Tiotropium bromide</li>\n</ul>\n<p><strong>Anti-inflammatory</strong></p>\n<ul>\n<li>Corticosteroids (Inhalational): Beclomethasone, Budesonide, Fluticasone</li>\n<li>Corticosteroids (Systemic): Prednisolone, Hydrocortisone</li>\n<li>Mast cell stabilizers: Sodium cromoglycate, Ketotifen</li>\n<li>Leukotriene antagonists: Montelukast, Zafirlukast</li>\n<li>anti-IgE - Omalizumab</li>\n</ul>\n</div>\n</div>\n</div>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following is not an S-phase inhibitor?",
    "choices": [
      {
        "id": 1,
        "text": "5-fluorouracil"
      },
      {
        "id": 2,
        "text": "Methotrexate"
      },
      {
        "id": 3,
        "text": "Hydroxyurea"
      },
      {
        "id": 4,
        "text": "Vincristine"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Vincristine</strong> is a vinca alkaloid that acts during the <strong>M phase</strong> of the cell cycle\u00a0</p>\n<p>It causes microtubule disruptions, thereby preventing cellular replication.</p>\n<p><strong>Vincristine</strong> prevents the polymerization of the microtubular protein tubulin, causing <strong>metaphase</strong> <strong>arrest</strong>. It is very useful for inducing remission in childhood <strong>acute</strong> <strong>lymphoblastic</strong> <strong>leukaemia</strong>. Prominent <strong>adverse</strong> <strong>effects</strong> are <strong>peripheral</strong> <strong>neuropathy</strong> and reversible <strong>alopecia</strong>. It also causes ataxia, nerve palsies, autonomic dysfunction and seizures.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A diabetic woman who did not respond well to metformin therapy was started on dapagliflozin. Which of the following is not true about this drug?",
    "choices": [
      {
        "id": 1,
        "text": "It increases risk of urinary tract infections"
      },
      {
        "id": 2,
        "text": "It acts by inhibiting SGLT-2 transporter on distal convoluted tubule"
      },
      {
        "id": 3,
        "text": "It promotes weight loss"
      },
      {
        "id": 4,
        "text": "It increases the risk of fractures"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Dapagliflozin </strong>acts by <strong>inhibiting </strong>the <strong>SGLT2 transporter </strong>present on the <strong>proximal segment </strong>of the <strong>renal tubule</strong>. SGLT2 transporter is present on the proximal segment of the renal tubule and not in the distal convoluted tubule.</p>\n<p>The <strong>SGLT2 transporter</strong> present in the proximal segment of the renal tubule is responsible for the <strong>reabsorption</strong> of <strong>80-90%</strong> of <strong>filtered glucose</strong>. Dapagliflozin acts by inhibiting this transporter resulting in <strong>glycosuria</strong> and decreasing the blood glucose level. This drug is effective <strong>orally</strong>. This drug also results in <strong>weight loss</strong>.<br /><br />Dapagliflozin has been approved by the FDA for the treatment of heart failure in both diabetic and non-diabetic patients.</p>\n<p>The common side effects of dapagliflozin include <strong>urinary tract infections</strong>, genital mycotic infections due to the high glucose content of the urine, and also <strong>increased</strong>\u00a0<strong>risk </strong>of <strong>fractures</strong>.</p>\n<p>Other SGLT2 inhibitors include <strong>empagliflozin</strong>, canagliflozin, and ertugliflozin.</p>\n<p>Empagliflozin has been found to decrease the risk of mortality from cardiovascular causes in diabetic patients.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 62-year-old woman came to the hospital with complaints of excruciating paroxysmal pain on the right side of her lips, gums, and cheek. The episodes last for 2-3 min and have been present for the past 2 months.  Which of the following is incorrect regarding the primary drug used in the treatment of this condition?",
    "choices": [
      {
        "id": 1,
        "text": "It can cause transient leukopenia"
      },
      {
        "id": 2,
        "text": "It is a GABAc receptor modulator"
      },
      {
        "id": 3,
        "text": "It also has anti-epileptic activity"
      },
      {
        "id": 4,
        "text": "It can lead to hyponatremia in the elderly"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The symptoms of\u00a0excruciating and paroxysmal facial pain are suggestive of <strong>trigeminal neuralgia.</strong>\u00a0<strong>Carbamazepine</strong>\u00a0is used as the <strong>primary</strong><strong>\u00a0drug</strong>\u00a0in this condition. The<strong> incorrect</strong> statement about carbamazepine is that it is a <strong>GABAc receptor modulator</strong>.\u00a0</p>\n<p>Carbamazepine acts by\u00a0<strong>slowing</strong>\u00a0the <strong>recovery rate</strong> of <strong>voltage-activated sodium channels</strong> from their inactivated state\u00a0and acts as a<strong> sodium channel blocker.\u00a0</strong></p>\n<p>It is used as the primary drug in both <strong>trigeminal</strong> and <strong>glossopharyngeal neuralgias</strong>. It is also the primary agent for treating <strong>generalized tonic-clonic</strong> and<strong> focal seizures</strong>. It can also be used in <strong>bipolar affective disorders</strong>.</p>\n<p>Carbamazepine also has a <strong>potentiating</strong> effect on the action of <strong>antidiuretic hormone</strong> (ADH). It can result in\u00a0water retention with decreased osmolarity and <strong>hyponatremia</strong>, especially in <strong>elderly</strong> patients with cardiac disease. Other adverse effects include:</p>\n<ul>\n<li>Hypersensitivity reactions\u00a0such as:\n<ul>\n<li>Stevens-Johnson syndrome</li>\n<li>Skin rashes</li>\n<li><strong>Transient leukopenia</strong></li>\n<li><strong>Aplastic anemia\u00a0</strong></li>\n<li>Agranulocytosis</li>\n<li><strong>Hepatotoxicity</strong> (on concomitant use with valproate)</li>\n</ul>\n</li>\n<li>Dose-related <strong>neurotoxicity</strong> such as:\n<ul>\n<li>vertigo</li>\n<li>ataxia</li>\n<li>diplopia and blurred vision</li>\n<li>worsening of seizures</li>\n<li>vomiting</li>\n</ul>\n</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient with endometrial cancer comes with pain in her right calf which is confirmed to be a thrombus by USG. Which of the following is preferred to be used in her to prevent propagation of the clot and why?",
    "choices": [
      {
        "id": 1,
        "text": "Low molecular weight heparin, short half life"
      },
      {
        "id": 2,
        "text": "Warfarin, long half life"
      },
      {
        "id": 3,
        "text": "Low molecular weight heparin, more bioavailability"
      },
      {
        "id": 4,
        "text": "Warfarin, lack of monitoring needed"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>The anticoagulant of choice for the management of<strong> cancer-associated thromboembolism</strong> is <strong>l</strong><strong>ow-molecular-weight heparin </strong>(LMWH). It is the preferred agent because of more <strong>bioavailability, lack</strong> of <strong>need</strong> for <strong>anticoagulant monitoring,</strong> and a <strong>long t1/2.\u00a0</strong></p>\n<p>Venous thromboembolism (including deep vein thrombosis, pulmonary embolism, and splanchnic vein thrombosis), is a frequent complication of cancer and is the second-leading cause of death in cancer patients receiving chemotherapy.</p>\n<p>Based on the results from the\u00a0<strong>C</strong>omparison of <strong>L</strong>ow-molecular-weight\u00a0heparin vs.\u00a0<strong>O</strong>ral anticoagulants for long-term anticoagulation in cancer patients with venous <strong>T</strong>hromboembolism (<strong>CLOT</strong>) Trial, all recent guidelines now advise LMWH for cancer-associated thromboembolism.\u00a0</p>\n<p>However, unfractionated heparin <strong>(UFH)</strong> can be used in patients with <strong>renal failure</strong>, and <strong>fondaparinux</strong> can be considered in patients with heparin-induced thrombocytopenia (<strong>HIT</strong>).</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Tacrine and malathion inhibit the Acetylcholine esterase enzyme by binding to which of the following site/sites?",
    "choices": [
      {
        "id": 1,
        "text": "Esteratic site, Anionic site"
      },
      {
        "id": 2,
        "text": "Anionic site, Esteratic site"
      },
      {
        "id": 3,
        "text": "Esteratic site"
      },
      {
        "id": 4,
        "text": "Anionic site"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Tacrine</strong> binds to the <strong>anionic site</strong> and <strong>malathion</strong> binds to the <strong>esteratic site </strong>of the Acetylcholine esterase enzyme and inhibits it.</p>\n<p><strong>Anticholinesterase drugs:<br /><br />Reversible inhibitors<br /></strong></p>\n<table style=\"border-collapse: collapse; width: 100.046%; height: 54.7578px;\" border=\"1\">\n<tbody>\n<tr style=\"height: 30.875px;\">\n<td style=\"width: 45.3989%; height: 30.875px;\"><strong>Carbamates</strong></td>\n<td style=\"width: 54.6464%; height: 30.875px;\"><strong>Non-Carbamates</strong></td>\n</tr>\n<tr style=\"height: 23.8828px;\">\n<td style=\"width: 45.3989%; height: 23.8828px;\">Physostigmine, Neostigmine, Pyridostigmine, Rivastigmine</td>\n<td style=\"width: 54.6464%; height: 23.8828px;\">Edrophonium, <strong>Tacrine</strong>, Donepezil, Galantamine</td>\n</tr>\n</tbody>\n</table>\n<p><strong><br />Irreversible inhibitors<br /></strong></p>\n<table style=\"border-collapse: collapse; width: 100%;\" border=\"1\">\n<tbody>\n<tr>\n<td style=\"width: 45.6897%;\"><strong>Carbamates</strong></td>\n<td style=\"width: 54.4011%;\"><strong>Organophosphates</strong></td>\n</tr>\n<tr>\n<td style=\"width: 45.6897%;\">Carbaryl, Propoxur</td>\n<td style=\"width: 54.4011%;\">Dyflos, Echthiophate, <strong>Malathion</strong>, Diazinon, Tabun, Sarin, Soman</td>\n</tr>\n</tbody>\n</table>\n<p><br />The AChE has two sites, an anionic site, and an esteratic site.<strong> </strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"><strong>Edrophonium and tacrine (Non-Carbamates) </strong>attach only to the <strong>anionic site </strong>and <strong>do not form</strong> <strong>covalent bonds</strong> with the enzyme. In contrast, <strong>organophosphates</strong> attach only to the <strong>esteratic site</strong> forming <strong>strong covalent bonds. Carbamates</strong> bind to both <strong>anionic and esteratic sites</strong>.</span></p>\n<div class=\"page\" title=\"Page 133\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Reactivation</strong> of edrophonium\u00ad inhibited enzyme occurs in <strong>&lt; 10 min</strong>, because the interaction is by forming <strong>weak hydrogen bonds</strong>, and does not involve hydrolysis of the inhibitor, but only its diffusion. <span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">The <strong>reactivation</strong> of <strong>carbamylated enzyme</strong> (1/2 to 6 hours) is <strong>less than</strong> that of the <strong>synthesis</strong> of fresh enzyme protein. In contrast, that of the<strong> phosphorylated enzyme</strong> (in days) is <strong>more than </strong>the <strong>regeneration time. </strong></span><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">The </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">phosphorylated enzyme</strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\"> may also undergo </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">\u2018ageing\u2019 </strong><span style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">by the loss of one of the alkyl groups and become </span><strong style=\"font-family: -apple-system, BlinkMacSystemFont, 'Segoe UI', Roboto, Oxygen, Ubuntu, Cantarell, 'Open Sans', 'Helvetica Neue', sans-serif;\">resistant to hydrolysis.</strong></p>\n</div>\n</div>\n</div>\n</div>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "An HIV-positive patient diagnosed with CMV retinitis was initiated on ganciclovir. Which ART drug among the following should be avoided?",
    "choices": [
      {
        "id": 1,
        "text": "Zidovudine"
      },
      {
        "id": 2,
        "text": "Efavirenz"
      },
      {
        "id": 3,
        "text": "Lamivudine"
      },
      {
        "id": 4,
        "text": "Dolutegravir"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p>In this clinical scenario, <strong>zidovudine</strong> has to be <strong>avoided</strong>. <strong>Ganciclovir</strong> used to treat <strong>CMV retinitis</strong> is associated with the risk of <strong>bone marrow suppression</strong>, leading to anaemia and neutropenia. <strong>Zidovudine</strong>, an <strong>antiretroviral drug, </strong>a nucleoside reverse transcriptase inhibitor, is also known to cause <strong>bone marrow suppression </strong>and can exacerbate these hematologic side effects when used with ganciclovir. Hence zidovudine has to be avoided in patients receiving ganciclovir to prevent enhanced bone marrow suppression.</p>\n<p>Other options</p>\n<p>Option B: <strong>Efavirenz</strong> is a non-nucleoside reverse transcriptase inhibitor that does not have significant bone marrow toxicity. Hence, it can be given along with ganciclovir.</p>\n<p>Option C: <strong>Lamivudine </strong>is a nucleoside reverse transcriptase inhibitor that is safe for patients receiving ganciclovir.</p>\n<p>Option D: <strong>Dolutegravir</strong>, an integrase inhibitor, is safe for patients receiving ganciclovir and does not have bone marrow side effects.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 16-year-old girl was taken to the emergency department with palpitations and restlessness after using a salbutamol inhaler 15 times in one hour following an asthma attack. Her chest examination was clear on auscultation, and cardiac examination showed tachycardia with a regular rhythm, without murmurs. What features are likely to be seen in this case?",
    "choices": [
      {
        "id": 1,
        "text": "Tall T waves on ECG"
      },
      {
        "id": 2,
        "text": "Hypoglycemia"
      },
      {
        "id": 3,
        "text": "Hyperkalemia"
      },
      {
        "id": 4,
        "text": "Muscle tremors"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p>Salbutamol toxicity can cause <strong>muscle tremors</strong> due to stimulation of<strong>\u00a0\u03b22-adrenergic</strong> receptors in skeletal muscle. It is the most common side effect. The risk is higher with elderly patients and those with COPD.</p>\n<p>Salbutamol is a relatively selective \u03b22- adrenergic receptor agonist.\u00a0In overdose, receptor specificity may be lost and stimulation of cardiac \u03b22-receptors may cause <strong>tachycardia</strong>, cardiac ischemia, and arrhythmias. It causes <strong>hypokalemia\u00a0</strong>(option C)\u00a0by stimulating \u03b22-receptors of the Na<sup>+</sup>/K<sup>+</sup> ATPase pump in the skeletal muscle, shifting K<sup>+</sup> intracellularly. This can produce ECG changes such as<strong> flattening and inversion of T</strong> <strong>waves </strong>(option A), <strong>QT prolongation,</strong> and <strong>U waves</strong>.\u00a0</p>\n<p>Acute salbutamol toxicity may cause <strong>lactic acidosis</strong>. \u03b22-adrenergic stimulation increases gluconeogenesis and lipolysis. This causes increased plasma glucose, leading to increased conversion of pyruvate and lactate. Overdose can result in <strong>hyperglycemia </strong>(option B), <strong>lactic acidosis</strong>, and <strong>cardiac arrhythmias</strong>.\u00a0</p>\n<p>Other adverse effects include hypoxemia and metabolic effects such as an <strong>increase in free fatty acids </strong>and\u00a0insulin. Desensitization is noted in the long-term use of salbutamol.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 66-year-old man presented with difficulty in urination and back pain. His PSA levels were found to be elevated and the x-ray pelvis revealed two osteoblastic lesions in the bony pelvis. Which of the following drugs can be used to treat the given condition?",
    "choices": [
      {
        "id": 1,
        "text": "Anastrozole"
      },
      {
        "id": 2,
        "text": "Desogestrel"
      },
      {
        "id": 3,
        "text": "Leuprolide"
      },
      {
        "id": 4,
        "text": "Spironolactone"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>The clinical features and investigations showing elevated PSA osteoblastic lesions in the pelvis are suggestive of <strong>metastatic</strong>\u00a0<strong>prostate</strong> <strong>cancer</strong>. <strong>Leuprolide </strong>is a <strong>GnRH</strong> <strong>agonist</strong> used in the treatment of prostate cancer.</p>\n<p><strong>Androgen deprivation therapy</strong> is the primary medical therapy for prostate cancer. The drugs used for this indication are\u00a0<strong>GnRH agonists</strong> such as <strong>goserelin</strong>, <strong>buserelin</strong>, <strong>leuprolide</strong>, <strong>nafarelin,</strong> and triptorelin.\u00a0The agonist action of the GnRH analogs causes an <strong>initial increase in LH</strong>, leading to <strong>increased testosterone</strong> production. This causes a <strong>tumor flare</strong>. This can be <strong>prevented by</strong> concomitant administration of an <strong>androgen receptor antagonist\u00a0</strong>such as <strong>flutamide</strong> or <strong>bicalutamide</strong>.</p>\n<p>After the initial period, there is a <strong>downregulation</strong> <strong>of GnRH receptors</strong> and changes in the downstream pathways, leading to a decrease in gonadotropins and testosterone (hypogonadotropic hypogonadism).\u00a0The androgen deprivation therapy with continuous GnRH agonist and an androgen receptor antagonist is <strong>as effective as surgical castration</strong> in reducing the levels of serum testosterone.</p>\n<p><strong>GnRH antagonists</strong> such as <strong>degarelix</strong> can also be used for androgen deprivation therapy. It has the advantage of <strong>not</strong> <strong>having a tumor flare phenomenon</strong>. However, because of the long-term safety profile of<strong> GnRH agonists</strong>, they are the <strong>preferred</strong> <strong>drugs</strong> for androgen deprivation therapy.</p>\n<p>Other options:</p>\n<p>Option A:<strong> Anastrozole</strong> is an <strong>aromatase inhibitor\u00a0</strong>used in the treatment of advanced breast cancer.</p>\n<p>Option B:\u00a0<strong>Desogestrel</strong> is a <strong>synthetic progestin</strong> without androgenic activity. It is used in combination with ethinyl estradiol for <strong>oral contraception</strong>.</p>\n<p>Option D:<strong> Spironolactone</strong>\u00a0is a potassium-sparing diuretic and <strong>aldosterone antagonist</strong>. It is a <strong>weak inhibitor of the androgen receptor</strong> and causes <strong>gynecomastia</strong> as a common side effect. It has been used in women to treat <strong>hirsutism</strong>.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "An HIV-positive patient was started on antiretroviral therapy. These drugs belong to which category?",
    "choices": [
      {
        "id": 1,
        "text": "Schedule H drugs"
      },
      {
        "id": 2,
        "text": "Schedule J drugs"
      },
      {
        "id": 3,
        "text": "Schedule X drugs"
      },
      {
        "id": 4,
        "text": "Schedule G drugs"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Schedule J </strong>contains a list of diseases that a <strong>drug may not prevent or cure</strong>.\u00a0E.g. - <strong>HIV </strong>&amp; <strong>Atherosclerosis</strong>.</p>\n<p><strong>The Drugs and Cosmetics Rules, 1945</strong> are the set of rules under The Drugs and Cosmetics Act,1940 which contains provisions for the classification of drugs under given schedules and there are guidelines for the storage, sale, display, and prescription of each schedule.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following drugs is representative of the graph as given below?",
    "choices": [
      {
        "id": 1,
        "text": "Penicillin"
      },
      {
        "id": 2,
        "text": "Amikacin"
      },
      {
        "id": 3,
        "text": "Ciprofloxacin"
      },
      {
        "id": 4,
        "text": "Gentamicin"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>The graph </strong>represents the<strong> time-dependent killing</strong> and is demonstrated by<strong> penicillin (Beta-lactam antibiotics)</strong> and <strong>macrolides.\u00a0</strong></p>\n<p>In antimicrobial pharmacodynamics, antibiotics are generally categorised based on how their antimicrobial action depends on time or concentration. \u00a0</p>\n<p>1.<strong> Time-dependent killing</strong>: These antibiotics rely on the <strong>amount of time</strong> the <strong>drug concentration</strong> remains <strong>above </strong>the <strong>minimum inhibitory concentration</strong> (MIC) to exert their effect. Once the concentration is above the MIC, increasing the concentration further does not significantly increase the rate of bacterial killing. Instead, the duration of exposure is key to effective bacterial eradication. This type is typically seen in <strong>beta-lactam antibiotics</strong>.\u00a0</p>\n<p><strong>Penicillins</strong>, <strong>cephalosporins</strong>, and <strong>vancomycin</strong> are examples of medications that demonstrate <strong>time-dependent killing</strong>. For these drugs, multiple daily doses are preferred over single doses.</p>\n<p>The image below shows time-dependent killing.</p>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/e2fbfcd7026a422b87211570339a0108.PNG"
    ],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/de59935081ef433c99266fa547e42bb2x866x722.PNG",
      "https://dhmbxeygs57ff.cloudfront.net/uploads/c1c5288ebe8f4f18af77726317f3d045x856x672.PNG"
    ]
  },
  {
    "text": "A 34-year-old man is seen over multiple visits for complaints of gastric ulcers despite the use of ranitidine. Further evaluation revealed elevated levels of gastrin and evidence of ulcers involving the jejunum suggesting a diagnosis of Zollinger-Ellison syndrome. Which of the following agents would be most useful in the management of this patient?",
    "choices": [
      {
        "id": 1,
        "text": "Famotidine"
      },
      {
        "id": 2,
        "text": "Lansoprazole"
      },
      {
        "id": 3,
        "text": "Misoprostol"
      },
      {
        "id": 4,
        "text": "Propantheline"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Lansoprazole\u00a0</strong>is the most useful in the management of this patient.</p>\n<p><strong>Lansoprazole</strong> is an H1/K1-ATPase proton pump inhibitor useful in the treatment of patients who have failed histamine H2-blocker therapy and patients with Zollinger-Ellison syndrome.</p>\n<p>Patients with Zollinger-Ellison syndrome develop <strong>pancreatic or duodenal gastrinomas</strong> that stimulate the secretion of very large amounts of acid, sometimes in the setting of <strong>multiple endocrine neoplasia, type I.\u00a0</strong>This can lead to <strong>severe gastroduodenal ulceration</strong> and other consequences of uncontrolled hyperchlorhydria.</p>\n<p><strong>Proton pump inhibitors</strong>\u00a0are activated by the proton-catalyzed formation of a tetracyclic sulfenamide. This leads to the trapping of the drug so that it does not diffuse back across the canalicular membrane. The activated compound forms a covalent bond with sulfhydryl groups of cysteines in the <strong>H<sup>+</sup>/K<sup>+\u00a0</sup>ATPase</strong> irreversibly, thus inactivating the pump molecule. They primarily promote healing of gastric and duodenal ulcers and is used to treat gastroesophageal reflux disease, including erosive esophagitis, that is complicated or unresponsive to treatment with H2 receptor antagonists. They are used along with antibiotics for the eradication of <em>Helicobacter pylori</em>. They are used as the mainstay treatment of pathological hypersecretory conditions, including the <strong>Zollinger-Ellison syndrome.</strong></p>\n<p>Other options:</p>\n<p>Option A- <strong>Famotidine</strong> is a histamine H2-blocker.</p>\n<p>Option C- <strong>Misoprostol</strong> is a prostaglandin analogue used to prevent ulcers in patients taking nonsteroidal anti-inflammatory drugs (NSAIDs).</p>\n<p>Option D- <strong>Propantheline</strong> is a quaternary ammonium anticholinergic agent which inhibits the muscarinic actions of acetylcholine on autonomic nerve endings. Propantheline were being used to alleviate symptoms of irritable bowel syndrome, painful gastrointestinal motility disorders and peptic ulcer disease. It has been replaced by more effective antiulcer agents.\u00a0</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient with peptic ulcer disease was prescribed ranitidine and sucralfate. The combination is incorrect because",
    "choices": [
      {
        "id": 1,
        "text": "Sucralfate interferes with absorption of ranitidine"
      },
      {
        "id": 2,
        "text": "Combination produces serious adverse effect like agranulocytosis"
      },
      {
        "id": 3,
        "text": "Ranitidine combines with sucralfate and interferes with its absorption"
      },
      {
        "id": 4,
        "text": "Ranitidine increases gastric pH so sucralfate is not able to act"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Ranitidine increases gastric pH</strong> and hence <strong>sucralfate</strong> is not able to polymerize as it requires an acidic pH to form a protective layer over the ulcer. Hence it is <strong>not</strong> a rational combination.</p>\n<p><strong>Sucralfate</strong>, in an acidic environment (<strong>pH &lt; 4</strong>) acts by producing a viscous, sticky polymer that adheres to ulcer craters and epithelial cells for <strong>up to 6 hours</strong> after a single dose. This viscous layer produced in the stomach leads to the inhibition of absorption of other drugs, like phenytoin, digoxin, cimetidine, ketoconazole, and fluoroquinolone antibiotics.\u00a0</p>\n<p><strong>Constipation</strong> is the most common <strong>side</strong> <strong>effect</strong> of sucralfate. It should be <strong>avoided in patients with renal failure</strong> who are at risk of aluminium overload. Aluminium-containing antacids should not be combined with sucralfate in these patients. \u00a0As the viscous gel produced by sucralfate is sticky, it may eventually lead to bezoar formation.</p>\n<p>It is generally used for prophylaxis of peptic ulcers, but rarely so because its side effects and its risks outweigh its benefits.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 35-year-old woman presents with persistent loss of interest in going to work, insomnia, fatigue, and reduced concentration at work for the past 3 weeks. She also had a history of myocardial infarction a year ago. Which drug is preferred for the management of this patient?",
    "choices": [
      {
        "id": 1,
        "text": "Imipramine"
      },
      {
        "id": 2,
        "text": "Duloxetine"
      },
      {
        "id": 3,
        "text": "Sertraline"
      },
      {
        "id": 4,
        "text": "Amitriptyline"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>In the given clinical scenario, the presentations of loss of interest in going to work, insomnia, fatigue, and reduced concentration at work for 3 weeks(&gt; 2 weeks) suggest that the patient is suffering from <strong>depression</strong>. <strong>Sertraline</strong>\u00a0is the preferred drug in treating <strong>depression</strong> in this patient with a <strong>history of myocardial infarction</strong> (MI), as it is <strong>cardio-safe</strong>.</p>\n<p><strong>Sertraline</strong> is a <strong>selective serotonin reuptake inhibitor</strong> (SSRI). SSRIs are generally considered <strong>safer</strong> in patients with a history of cardiovascular disease, as they have a relatively low risk of cardiotoxicity.</p>\n<p><strong>Non-selective serotonin reuptake inhibitors </strong>are usually <strong>cardiotoxic</strong>.\u00a0</p>\n<p>\u00a0The various drug classes used in depression and anxiety are listed below:</p>\n<table style=\"border-collapse: collapse; width: 46.1716%;\" border=\"1\">\n<tbody>\n<tr>\n<td style=\"width: 29.96%;\">Class of drugs</td>\n<td style=\"width: 70.0416%;\">Examples</td>\n</tr>\n<tr>\n<td style=\"width: 29.96%;\">Selective serotonin reuptake inhibitors (SSRI)<br /><br /></td>\n<td style=\"width: 70.0416%;\">\n<ul>\n<li>Fluoxetine</li>\n<li>Fluvoxamine</li>\n<li>Paroxetine</li>\n<li><strong>Sertraline</strong></li>\n<li>Citalopram</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td style=\"width: 29.96%;\">Serotonin-norepinephrine reuptake inhibitors<br />(non-selective)</td>\n<td style=\"width: 70.0416%;\">\n<ul>\n<li>Venlafaxine, desvenlafaxine</li>\n<li><strong>Duloxetine</strong></li>\n<li>Milnacipran</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td style=\"width: 29.96%;\">Tricyclic antidepressants<br />(non-selective)</td>\n<td style=\"width: 70.0416%;\">\n<ul>\n<li><strong>Amitriptyline</strong></li>\n<li><strong>Imipramine</strong></li>\n<li>Nortriptyline</li>\n<li>Desipramine</li>\n<li>Amoxapine</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td style=\"width: 29.96%;\">Atypical antipsychotics<br /><br /></td>\n<td style=\"width: 70.0416%;\">\n<ul>\n<li>Aripiprazole</li>\n<li>Olanzapine</li>\n<li>Quetiapine</li>\n<li>Risperidone</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td style=\"width: 29.96%;\">Monoamine oxidase inhibitors (MAO)<br /><br /></td>\n<td style=\"width: 70.0416%;\">\n<ul>\n<li>Isocarboxazid</li>\n<li>Selegiline</li>\n<li>Phenelzine</li>\n</ul>\n</td>\n</tr>\n<tr>\n<td style=\"width: 29.96%;\">Atypical antidepressants<br /><br /></td>\n<td style=\"width: 70.0416%;\">\n<ul>\n<li>Bupropion</li>\n<li>Trazodone</li>\n<li>Mirtazapine</li>\n<li>Mianserin</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table>\n<p><strong>Depression</strong> or major depressive disorder is a mood disorder in which the individual experiences <strong>at least 5</strong> of the following symptoms during <strong>2 weeks</strong> and is a change from previous functioning along with either a depressed mood or a loss of interest or pleasure.</p>\n<ul>\n<li><strong>Depressed mood </strong>most of the day, nearly every day (feeling sad, empty, hopeless) or as an observa\u00adtion made by others</li>\n<li>Markedly <strong>diminished interest</strong> or pleasure in all or almost all activities</li>\n<li>Significant weight loss/weight gain or change in appetite</li>\n<li><strong>Insomnia</strong> or hypersomnia</li>\n<li>Psychomotor agitation or retardation</li>\n<li><strong>Fatigue</strong> or loss of energy</li>\n<li>Feelings of worthlessness or excessive or inappropriate guilt</li>\n<li><strong>Difficulty thinking or concentrating</strong>, or indecisiveness</li>\n<li>Recurrent thoughts of death, suicidal ideation, or a suicide attempt\u00a0</li>\n</ul>\n<p>Other options:\u00a0</p>\n<p>Option A and D: <strong>Imipramine</strong> and <strong>amitriptyline</strong> are <strong>tricyclic antidepressants</strong> (TCAs), which are associated with a higher risk of <strong>cardiac side effects</strong> (e.g., arrhythmias, QT prolongation). Therefore, they are not preferred in this patient with a history of MI.</p>\n<p>Option B: <strong>Duloxetine</strong> is a <strong>serotonin-norepinephrine reuptake inhibitor</strong> (SNRI), which is associated with <strong>cardiac side effects</strong>. Hence, it is not preferred in this patient with a history of MI.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 40-year-old male patient has been prescribed a drug that catalyzes the enzymatic oxidation of uric acid into allantoin for the treatment of his chronic gout. What is this drug?",
    "choices": [
      {
        "id": 1,
        "text": "Colchicine"
      },
      {
        "id": 2,
        "text": "Febuxostat"
      },
      {
        "id": 3,
        "text": "Pegloticase"
      },
      {
        "id": 4,
        "text": "Allopurinol"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>The drug that catalyzes the enzymatic oxidation of uric acid into allantoin for the treatment of chronic gout is<strong> pegloticase. </strong></p>\n<p>Pegloticase is a <strong>pegylated uricase</strong> (urate oxidase) that catalyzes the enzymatic oxidation of <strong>uric acid into allantoin</strong>, which is a more soluble and inactive metabolite.\u00a0It is used in the treatment of <strong>severe</strong>,\u00a0<strong>refractory chronic gout</strong> or in cases where other urate-lowering therapies are contraindicated. The efficacy of this drug gets lowered if antibodies are produced against the drug, which occurs in many patients. This also increases the risk of infusion reactions.\u00a0</p>\n<div class=\"page\" title=\"Page 711\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<div class=\"page\" title=\"Page 711\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Rasburicase</strong> is a <strong>recombinant uricase</strong>. It is indicated for the initial management of elevated plasma uric acid levels in patients with malignancies who are on chemotherapy. The efficacy is limited by the production of antibodies to the drug.</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n<p><strong>Gout</strong> occurs due to the precipitation of urate crystals in the tissues with a subsequent inflammatory response. In an acute episode of gout, there is painful distal monoarthritis which can lead to joint destruction, subcutaneous tophi, and renal calculi. Management of gout includes:</p>\n<div class=\"page\" title=\"Page 708\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<ul>\n<li>Reduction of pain and inflammation: NSAIDs, colchicine, glucocorticoids</li>\n<li>Inhibition of the formation of urate: Allopurinol, febuxostat</li>\n<li>Promotion of urate excretion: Probenecid, lesinurad</li>\n</ul>\n</div>\n</div>\n</div>\n</div>\n<p>Other options:\u00a0</p>\n<p>Option A: <strong>Colchicine</strong> acts by <strong>preventing the polymerization of microtubules by tubulin</strong>, this <strong>reduces neutrophil recruitment</strong> to inflamed tissue and also <strong>decreases the secretion of chemotactic factors</strong> by activated neutrophils. Overall reducing the inflammatory response.</p>\n<p>Option B:\u00a0<strong>Febuxostat</strong> is a\u00a0<strong>xanthine oxidase inhibitor</strong> approved for the <strong>treatment of hyperuricemia</strong> in patients with gout.</p>\n<p>Option D: <strong>Allopurinol</strong> by <strong>inhibiting the xanthine oxidase</strong> enzyme prevents the conversion of xanthine to uric acid.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A pregnant female at 36 weeks gestation, presents with palpitations, protrusion of the eyeball, and heat intolerance. On blood investigations, it was found that she had increased T3 and T4 levels and decreased TSH levels.  Which of the following should be the next step in the management of this patient?",
    "choices": [
      {
        "id": 1,
        "text": "Methimazole"
      },
      {
        "id": 2,
        "text": "Subtotal thyroidectomy"
      },
      {
        "id": 3,
        "text": "Propylthiouracil"
      },
      {
        "id": 4,
        "text": "Radioactive iodine"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p>In the given clinical scenario, the most likely diagnosis is <strong>thyrotoxicosis</strong>. As she is in her<strong> third trimester</strong>, the drug of choice for the treatment of thyrotoxicosis is <strong>methimazole.</strong></p>\n<p>Treatment of thyrotoxicosis in pregnancy has been summarized in the table below.</p>\n<table style=\"border-collapse: collapse; width: 38.5561%;\" border=\"1\">\n<tbody>\n<tr>\n<td style=\"width: 50.0766%; text-align: center;\">Trimester</td>\n<td style=\"width: 49.9234%; text-align: center;\">Treatment options</td>\n</tr>\n<tr>\n<td style=\"width: 50.0766%;\">First trimester</td>\n<td style=\"width: 49.9234%;\">\n<p>Propylthiouracil</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 50.0766%;\">Second trimester</td>\n<td style=\"width: 49.9234%;\">Methimazole (preferred)<br />Subtotal thyroidectomy</td>\n</tr>\n<tr>\n<td style=\"width: 50.0766%;\"><strong>Third trimester</strong></td>\n<td style=\"width: 49.9234%;\"><strong>Methimazole</strong></td>\n</tr>\n</tbody>\n</table>\n<p><strong>Thyrotoxicosis</strong> during pregnancy is usually controlled by thioamide drugs. <strong>Propylthiouracil</strong> was preferred previously because it partially inhibits the conversion of T4 to T3 and crosses the placenta less readily than methimazole. However, since it has a <strong>higher risk </strong>of causing <strong>propylthiouracil-associated liver failure in pregnancy</strong>, <strong>methimazole</strong> is prescribed according to guidelines in<strong>\u00a0</strong>the<strong> </strong>second trimester<strong> and third trimesters</strong>.\u00a0Methimazole is usually avoided in the first trimester due to <strong>methimazole-associated embryopathy.</strong>\u00a0</p>\n<p>Other options:</p>\n<p>Option B: <strong>Subtotal thyroidectomy</strong> is done once the hyperthyroidism is medically controlled. It is usually avoided during pregnancy, however, may be done in some cases in the second trimester where it can't be controlled via medication.</p>\n<p>Option D: <strong>Radioactive iodine</strong> is <strong>contraindicated</strong> in pregnant women as it may cause <strong>fetal thyroid gland destruction</strong>.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient is diagnosed with gastroparesis. Which of the following drugs cannot be used to treat this condition?",
    "choices": [
      {
        "id": 1,
        "text": "Cisapride"
      },
      {
        "id": 2,
        "text": "Loperamide"
      },
      {
        "id": 3,
        "text": "Metoclopramide"
      },
      {
        "id": 4,
        "text": "Motilin"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>Gastroparesis can be treated with <strong>prokinetic agents </strong>such as <strong>metoclopramide, cisapride, </strong>and<strong> motilin</strong>. <strong>Loperamide</strong> is an orally active <strong>antimotility</strong> and <strong>antisecretory agent\u00a0</strong>and <strong>cannot</strong> be used to treat gastroparesis.</p>\n<p>Loperamide acts by <strong>increasing</strong> the mouth to the caecum and small intestine <strong>transit times</strong> and increases the tone of the anal sphincter.</p>\n<div class=\"page\" title=\"Page 928\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Prokinetic agents enhance coordinated GI motility and the transit of material in the GI tract. They do not interfere with the normal physiological pattern and rhythm of motility. They act through the following mechanisms of action:</p>\n<ul>\n<li><strong>Dopamine</strong> receptor <strong>antagonists</strong>: Metoclopramide and domperidone</li>\n<li><strong>Serotonin</strong> receptor <strong>agonists</strong>: cisapride and prucalopride</li>\n<li>Mimicking<strong> motilin</strong> action: Erythromycin and other macrolide antibiotics</li>\n</ul>\n<p>Indications for use of prokinetic agents such as metoclopramide include gastroparesis, in medical or diagnostic procedures such as <strong>upper endoscopy</strong> or contrast radiography of the GI tract and ameliorate nausea and vomiting that often accompany GI dysmotility syndromes.</p>\n</div>\n</div>\n</div>\n</div>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A middle-aged male patient was found to have multidrug-resistant tuberculosis.  He is started on the intensive phase of treatment according to standard RNTCP guidelines. A week after treatment, he develops features of frank psychosis. Which of the following drugs is likely to have caused this?",
    "choices": [
      {
        "id": 1,
        "text": "Amikacin"
      },
      {
        "id": 2,
        "text": "Cycloserine"
      },
      {
        "id": 3,
        "text": "Capreomycin"
      },
      {
        "id": 4,
        "text": "Rifampicin"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Cycloserine</strong> is likely to have caused features of <strong>frank psychosis</strong>.</p>\n<p>It is an <strong>oral</strong>\u00a0<strong>second-line antitubercular drug</strong> that inhibits <em>M. tuberculosis</em>\u00a0and, according to RNTCP guidelines, is given during the <strong>intensive phase</strong> of treating <strong>multi-drug resistant TB</strong>.</p>\n<p>This drug has the nickname, <strong>pych-serine</strong>, due to its strong association with <strong>neuropsychiatric</strong> adverse effects. Symptoms range from headache and somnolence to severe <strong>psychosis,</strong> seizures, and suicidal ideas.\u00a0Therefore, it is contraindicated in epilepsy and given with caution in patients with depression. <strong>Pyridoxine 100 mg/day</strong> should be given to <strong>reduce neuropsychiatric</strong> symptoms.</p>\n<p>Other options:\u00a0</p>\n<p>Options A and C: <strong>Amikacin</strong> (aminoglycoside) and <strong>capreomycin</strong> (cyclic peptide analogue) are<strong> injectables</strong> that are also used as <strong>second-line antitubercular drugs</strong>. They cause ototoxicity and nephrotoxicity.\u00a0</p>\n<p>Option D: <strong>Rifampicin</strong> is a <strong>first-line anti-TB drug</strong> that is used to treat <strong>drug-sensitive</strong> TB. Other first-line drugs include <strong>isoniazid</strong>, <strong>pyrazinamide</strong>, and <strong>ethambutol</strong>.\u00a0</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Oral digoxin is being given to a 65-year-old male patient with congestive heart failure as a maintenance dose to gradually digitalize him. A target plasma concentration of 0.70 ng/mL is decided upon. The digoxin clearance for this particular individual is calculated as 60 mL/min. Knowing that the oral bioavailability of digoxin is 70%, what is the dosing rate in this patient?",
    "choices": [
      {
        "id": 1,
        "text": "50 ng/min"
      },
      {
        "id": 2,
        "text": "60 ng/min"
      },
      {
        "id": 3,
        "text": "70 ng/min"
      },
      {
        "id": 4,
        "text": "80 ng/min"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The dosing rate in this patient is\u00a0<strong>60 ng/min.</strong></p>\n<p>The <strong>oral bioavailability of digoxin is 70% (F = 0.7)</strong> and the required target plasma concentration (Cp) is <strong>0.70 ng/mL</strong>. <strong>CL</strong> is the clearance of digoxin which is\u00a060 mL/min.</p>\n<p>Hence, the appropriate dose rate for this patient can be calculated as:</p>\n<p><strong>Dosing rate = Target Cp x CL/F</strong></p>\n<p>= [0.70 ng/mL \u00d7 60 mL/min] \u00f7 [0.7]</p>\n<p>= <strong>60 ng/min</strong></p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 45-year-old woman with type 2 diabetes mellitus is being treated with oral antidiabetic drugs. She has a history of hypothyroidism and is on levothyroxine therapy. Routine blood tests reveal low TSH levels and normal free T4 and T3 levels. Which of the following drugs may be responsible for this patient's blood test results?",
    "choices": [
      {
        "id": 1,
        "text": "Metformin"
      },
      {
        "id": 2,
        "text": "Dapagliflozin"
      },
      {
        "id": 3,
        "text": "Sitagliptin"
      },
      {
        "id": 4,
        "text": "Glibenclamide"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Metformin</strong> is the most likely cause of <strong>low TSH levels</strong> and <strong>normal free T4 and T3 levels</strong> in this patient.</p>\n<p><strong>Metformin</strong> belongs to the <strong>biguanide</strong> class of oral hypoglycemic drugs. Metformin is accepted as the <strong>first-line treatment</strong> of <strong>type 2 diabetes</strong> and is the most commonly used oral agent for this condition. It acts primarily by inhibiting hepatic gluconeogenesis. It activates <strong>AMP-dependent protein kinase</strong>, leading to stimulation of hepatic fatty acid oxidation, glucose uptake, and nonoxidative glucose metabolism and reduction of lipogenesis and gluconeogenesis.</p>\n<p>Metformin is associated with <strong>decreased TSH</strong> levels. It also prevents an increase in the thyroid volume.</p>\n<p>Other options:</p>\n<p>Option B: <strong>Dapagliflozin</strong>, a sodium-glucose co-transporter-2 <strong>(SGLT-2) inhibitor</strong>, is not known to affect thyroid function.</p>\n<p>Option C: <strong>Sitagliptin</strong>, a dipeptidyl peptidase-4<strong> (DPP-4) inhibitor</strong>, has no significant effects on thyroid function.</p>\n<p>Option D: <strong>Glibenclamide</strong>, a <strong>sulfonylurea</strong>, also does not impact thyroid function.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 17-year-old girl was admitted with a large wound on her thigh for the past 3 months. Cultures from the wound margin revealed an MRSA infection. She was given an antibiotic that binds to the subunit of the ribosome marked by the red cross and inhibits bacterial protein synthesis. Identify the drug given to this patient.",
    "choices": [
      {
        "id": 1,
        "text": "Chloramphenicol"
      },
      {
        "id": 2,
        "text": "Linezolid"
      },
      {
        "id": 3,
        "text": "Vancomycin"
      },
      {
        "id": 4,
        "text": "Gentamicin"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><span data-preserver-spaces=\"true\">The drug given in this case is\u00a0</span><strong>Linezolid</strong>\u00a0which binds to the\u00a0<strong>P site </strong>of the<strong> 50s ribosomal subunit\u00a0</strong>and<strong>\u00a0</strong>inhibits bacterial protein synthesis. It is an\u00a0<strong>oxazolidinone\u00a0</strong>that\u00a0is active against various resistant organisms including methicillin-resistant staphylococci, vancomycin-resistant staphylococci.\u00a0Linezolid is well absorbed orally and the<strong>\u00a0bioavailability </strong>approaches<strong> 100%.</strong></p>\n<p>Linezolid and tedizolid are FDA approved for the treatment of skin and soft tissue infections caused by streptococci and staphylococcus aureus (MSSA and MRSA).\u00a0Linezolid is also approved for the treatment of community-acquired pneumonia due to S. pneumoniae and nosocomial pneumonia due to S. aureus.</p>\n<p>Adverse efffects of linezolid:</p>\n<ul>\n<li><strong>Myelosuppression\u00a0</strong>(anemia, leukopenia, pancytopenia)</li>\n<li><strong>Thrombocytopenia</strong><strong>\u00a0</strong>(most common side effect)\u00a0</li>\n<li><strong>Serotonin syndrome</strong> if given along with serotonergic drugs due to <strong>monoamine oxidase\u00a0</strong>(MAO)<strong> inhibition</strong></li>\n<li>Mitochondrial toxicities like peripheral neuropathy, optic neuropathy, lactic acidosis</li>\n</ul>\n<p>Clinical correlate- Intravenous and oral doses for linezolid are the same because of 100% bioavailability.</p>\n<p>Other options:</p>\n<p>Option A -\u00a0<strong><span data-preserver-spaces=\"true\">Chloramphenicol</span></strong>\u00a0primarily binds<strong><span data-preserver-spaces=\"true\">\u00a0reversibly </span></strong>to the<strong><span data-preserver-spaces=\"true\"> 50S ribosomal subunit.</span></strong><span data-preserver-spaces=\"true\">\u00a0It blocks the amino acid\u2013containing end of the aminoacyl tRNA from binding to the acceptor site on the 50S ribosomal subunit. This prevents the peptide bond formation by breaking the interaction between peptidyl transferase and its amino acid substrate. One of the most important adverse effects of chloramphenicol is\u00a0<strong>grey baby syndrome.</strong></span></p>\n<p>Option C -\u00a0<strong>Vancomycin</strong> is a glycopeptide.<strong>\u00a0</strong>It<strong>\u00a0</strong>inhibits bacterial cell wall synthesis by binding with <strong>D-alanyl-D-alanine.\u00a0</strong>It is used in the treatment of MRSA, clostridium difficile, and enterococci.\u00a0<strong>Redman syndrome, ototoxicity,\u00a0</strong>and<strong> nephrotoxicity\u00a0</strong>are the most important adverse effects.</p>\n<p>Option D -\u00a0<strong>Gentamicin\u00a0</strong>is an\u00a0<strong>aminoglycoside. </strong>Aminoglycoside antibiotics act by\u00a0binding to the <strong>30s ribosome</strong> and interfere with the initiation of protein synthesis. Their ability to cause misreading of DNA template and the formation of aberrant proteins that get incorporated into bacterial cell membrane makes them\u00a0bactericidal agents. Their antimicrobial activity reduces in an anaerobic environment. <strong>Ototoxicity, nephrotoxicity,\u00a0</strong>and <strong>neuromuscular blockade</strong> are the most important adverse effects.</p>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/d9552ad6e0c144d799b50a3792d13d70.JPEG"
    ],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/ee45ba38cfce413fbfb460f29cb399ecx1280x1343.JPEG"
    ]
  },
  {
    "text": "A patient with chronic angina was prescribed a new drug, ranolazine. This drug acts by which of the following mechanism?",
    "choices": [
      {
        "id": 1,
        "text": "Inhibit funny currents in SA node"
      },
      {
        "id": 2,
        "text": "Late sodium current inhibition"
      },
      {
        "id": 3,
        "text": "Rho-kinase inhibitor"
      },
      {
        "id": 4,
        "text": "K+ ATP channel agonist"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Ranolazine</strong> acts by\u00a0<strong>late sodium current</strong>\u00a0<strong>inhibition\u00a0</strong>in the heart.\u00a0It is used in the prophylaxis of <strong>angina.</strong></p>\n<p>Late sodium current (I<sub>Na</sub>) facilitates the entry of calcium via the sodium-calcium exchanger. <strong>Inhibition</strong> of\u00a0<strong>I<sub>Na</sub>,</strong> therefore, reduces the intracellular calcium concentration which in turn reduces the diastolic tension and cardiac contractility.</p>\n<p>At higher doses, it may also modify the fatty acid oxidation (<strong>pFOX inhibitor</strong>), which improves the efficiency of cardiac oxygen utilisation but whether this actually occurs at therapeutic doses is still being studied. It also has mild beta-blocking activity.</p>\n<p>Ranolazine is the second-line FDA-approved drug for heart failure. Side effects of ranolazine include dizziness, headache, and postural hypotension.</p>\n<p>Other options:</p>\n<p>Option A:\u00a0<strong>Ivabradine </strong>selectively <strong>blocks the funny current (I<sub>f</sub></strong><strong>) channel\u00a0</strong>involved in the generation of automaticity in the SA node. It reduces heart rate and thereby oxygen demand. It does not have any effect on cardiac contractility. It is an FDA-approved drug for the treatment of <strong>heart failure</strong>. It is also used for treating stable angina.</p>\n<p>Option C:\u00a0<strong>Fasudil</strong>\u00a0acts by<strong> inhibiting</strong> smooth muscle <strong>Rho kinase</strong> and reduces coronary vasospasm.</p>\n<p>Option D:\u00a0<strong>Nicorandil</strong> acts as an agonist at ATP-sensitive potassium (K<sub>ATP</sub>) channels i.e. <strong>potassium channel opener</strong>. It decreases afterload and preload of the heart by its vasodilatory properties at both arterioles and venules. It is used for the treatment of stable angina.</p>\n<p>Note: <strong>Trimetazidine</strong> is a\u00a0<strong>pFOX inhibitor\u00a0</strong>that partially inhibits fatty acid oxidation in the myocardium. Thereby, it decreases the oxygen requirement. It is also used as an anti-anginal agent.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following drugs act by reversible inhibition of P2Y12 receptor?",
    "choices": [
      {
        "id": 1,
        "text": "Clopidogrel"
      },
      {
        "id": 2,
        "text": "Ticagrelor"
      },
      {
        "id": 3,
        "text": "Prasugrel"
      },
      {
        "id": 4,
        "text": "Ticlopidine"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Ticagrelor</strong> is a <strong>reversible inhibitor</strong>\u00a0of <strong>P2Y12 receptor</strong>.</p>\n<p>Injury to the vessel wall exposes the subendothelial collagen and causes platelets to adhere and activate at the site. <strong>Activated platelets release ADP</strong>, which <strong>binds to P2Y12 receptors</strong> on other platelets in the circulation and causes their activation. This can cause <strong>amplifying cycles of clot formation</strong> and <strong>complete occlusion of the blood vessels</strong>. This is especially dangerous in patients with atherosclerotic plaques in the coronary arteries. Any <strong>acute plaque change</strong>, such as ulceration, can lead to <strong>thrombosis</strong> and <strong>acute coronary syndromes</strong>.\u00a0</p>\n<p>This is where anti-platelet drugs such as P2Y12 inhibitors come in. P2Y12 inhibitors include clopidogrel, prasugrel, ticagrelor and cangrelor. Some of the features of these drugs are summarized below:</p>\n<table style=\"width: 82.4864%;\">\n<tbody>\n<tr>\n<td style=\"width: 9.62761%;\"><strong>Clopidogrel</strong></td>\n<td style=\"width: 14.1689%;\"><strong>Irreversible</strong> P2Y12 antagonist, oral</td>\n<td style=\"width: 76.2035%;\">\n<p>It is a <strong>prodrug</strong>; that requires activation by <strong>CYP 2C19</strong> to work.</p>\n<p>Blocks platelet aggregation for the entire lifetime of platelets</p>\n<p><strong>PPIs</strong> such as omeprazole and pantoprazole <strong>inhibit CYP 2C19</strong>, thus r<strong>educing the formation of the active metabolite</strong> of clopidogrel and leading to therapeutic failure.</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 9.62761%;\"><strong>Prasugrel</strong></td>\n<td style=\"width: 14.1689%;\"><strong>Irreversible</strong> P2Y12 antagonist, oral</td>\n<td style=\"width: 76.2035%;\">It has a more <strong>rapid onset</strong> of action compared to clopidogrel.</td>\n</tr>\n<tr>\n<td style=\"width: 9.62761%;\"><strong>Ticagrelor</strong></td>\n<td style=\"width: 14.1689%;\"><strong>Reversible</strong> P2Y12 antagonist, oral</td>\n<td style=\"width: 76.2035%;\">\n<p>More <strong>rapid onset and offset</strong> of action compared to clopidogrel.</p>\n<p>Associated with <strong>dyspnea</strong> and <strong>higher risk of intracranial bleeding</strong>; contraindicated in patients with a history of intracranial bleeding.</p>\n</td>\n</tr>\n<tr>\n<td style=\"width: 9.62761%;\"><strong>Cangrelor</strong></td>\n<td style=\"width: 14.1689%;\"><strong>Reversible</strong> P2Y12 antagonist, <strong>intravenous</strong></td>\n<td style=\"width: 76.2035%;\">The action begins within minutes and lasts for one hour following the stoppage of the drug.</td>\n</tr>\n</tbody>\n</table>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following drugs does not represent the action of the graph labelled as '4'?",
    "choices": [
      {
        "id": 1,
        "text": "Pimavanserin"
      },
      {
        "id": 2,
        "text": "Beta-carbolines"
      },
      {
        "id": 3,
        "text": "Varenicline"
      },
      {
        "id": 4,
        "text": "Rimonabant"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>Graph 4</strong> represents an <strong>inverse agonist</strong>. Among the given options, <strong>varenicline</strong> is <strong>not </strong>an <strong>inverse agonist</strong>. It is a <strong>partial agonist</strong>.</p>\n<p><strong>Inverse agonist</strong> (graph 4): An agent that activates a receptor to produce an effect in the opposite direction of the agonist. <br />Examples:</p>\n<ul>\n<li><strong>Pimavanserin</strong> is an inverse agonist at 5HT2A\u00a0</li>\n<li><strong>\u03b2-Carboline</strong> is an inverse agonist at the benzodiazepine site of the GABA-A receptor.</li>\n<li><strong>Rimonabant</strong> is an inverse agonist at cannabinoid receptor.\u00a0\u00a0</li>\n</ul>\n<div><strong>Graph 1 </strong>represents the <strong>agonist: </strong>An agonist is an agent that initiates the <strong>normal</strong> <strong>physiological response</strong> when combined with a receptor. Eg: <strong>Salbutamol</strong> is a beta-2 receptor agonist.</div>\n<div style=\"padding-left: 30px;\">\u00a0</div>\n<div><strong>Graph 2</strong> represents a <strong>partial agonist</strong>: An agent that produces a <strong>submaximal or partial effect</strong> when combined with a receptor. Eg: <strong>B</strong><span class=\"ILfuVd\" lang=\"en\"><span class=\"hgKElc\"><strong>uprenorphine</strong> and butorphanol are partial agonists at opioid receptors.</span></span></div>\n<div style=\"padding-left: 30px;\">\u00a0</div>\n<div><strong>Graph 3 </strong>represents the <strong>competitive</strong>\u00a0<strong>antagonist</strong>: An agent which blocks or reduces the action of an agonist on a receptor, but does not have any effect of its own. Eg: N<span class=\"ILfuVd\" lang=\"en\"><span class=\"hgKElc\">altrexone and <strong>naloxone</strong> are antagonists at opioid receptors</span></span></div>\n<div style=\"padding-left: 30px;\">\u00a0</div>\n<div>The image given below shows the action of various types of selective receptor modulators:</div>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/47a42dafb55b40a8a33cfebc2d871081.JPEG"
    ],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/8d7167c153aa42a5bdc0787fd454473ex1280x1252.JPEG"
    ]
  },
  {
    "text": "Dextromethorphan used as an antitussive agent is a:",
    "choices": [
      {
        "id": 1,
        "text": "Local anesthetic"
      },
      {
        "id": 2,
        "text": "Neuromodulator"
      },
      {
        "id": 3,
        "text": "Medullary opioid receptor agonist"
      },
      {
        "id": 4,
        "text": "NMDA receptor antagonist"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Dextromethorphan\u00a0</strong>is a<strong> centrally-acting NMDA\u00a0receptor antagonist </strong>that is used as an <strong>antitussive</strong>.</p>\n<p>The <strong>antitussive</strong> action of <strong>dextromethorphan</strong> is due to the <strong><em>d</em>-isomer</strong>, whereas the <strong><em>l</em>-isomer</strong> is an <strong>analgesic.</strong></p>\n<p><strong>Hallucinations</strong> at higher doses, gastrointestinal discomfort, and dizziness are well-known side effects. Dextromethorphan must be administered with caution to those with abuse potential.</p>\n<p><strong>Antitussives</strong> are a group of drugs that act centrally to <strong>raise the threshold of the cough centre</strong> or peripherally on the respiratory tract to reduce the tussal impulse or both.</p>\n<p>The mechanism of action of other antitussives is as follows:\u00a0</p>\n<ul>\n<li><strong>Local anaesthetic action </strong>(option A)<strong>\u00a0</strong>is seen in benzonatate<strong>\u00a0</strong>which acts<strong> peripherally </strong>by<strong> anaesthetising the stretch receptors</strong> located in the respiratory passages, lungs and pleura. By decreasing the activity of these stretch receptors, benzonatate may <strong>reduce the cough reflex</strong>. Side effects include <strong>dysphagia</strong> and <strong>dizziness</strong>. Acute ingestion may cause <strong>seizures</strong> and <strong>cardiac arrest</strong>.</li>\n<li><strong>Neuromodulators</strong> (Option B) such as <strong>gabapentin</strong> and pregebalin\u00a0inhibits neurotransmission.They are beneficial in neuropathic pain syndrome and <strong>chronic</strong> <strong>idiopathic</strong> <strong>cough</strong>. Side effects are somnolence and dizziness.</li>\n<li><strong>Opioids</strong> (Option C) such as <strong>codeine</strong> and pholcodine act centrally on the <strong>medullary opioid receptor</strong> in the medullary cough centre. Side effects include sedation and constipation.</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following nomograms is used for paracetamol poisoning ?",
    "choices": [
      {
        "id": 1,
        "text": "Rumack matthew"
      },
      {
        "id": 2,
        "text": "Matzke"
      },
      {
        "id": 3,
        "text": "Halsted"
      },
      {
        "id": 4,
        "text": "Salazar"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Rumack Matthew</strong> nomogram is used in <strong>paracetamol poisoning</strong>. In this nomogram serum <strong>acetaminophen concentration</strong> is measured for the time after ingestion which is useful in assessing potential <strong>hepatotoxicity</strong> after an acute ingestion of paracetamol.</p>\n<p><strong>Acetaminophen toxicity</strong> clinically presents with nausea, vomiting, diarrhea, and abdominal pain. Later, renal failure and myocardial injury may be seen. <strong>Low bilirubin levels</strong> along with <strong>raised aminotransferase</strong> levels are characteristic of the condition.\u00a0</p>\n<p><strong>Acetaminophen toxicity</strong> is an important cause of <strong>acute liver failure</strong>. Ingestion of \u226525g can be fatal. Cytochrome P450 CYP2E1 metabolizes acetaminophen to <strong>N-acetyl-p-benzoquinone-imine</strong> (NAPQI). <strong>Glutathione</strong> is responsible for its detoxification, after which it is excreted in the urine. When glutathione reserves are depleted or large amounts of NAPQI are formed, it binds to hepatocyte macromolecules. This can then lead to hepatocyte necrosis.</p>\n<p>Initial management includes <strong>gastric lavage</strong> and <strong>oral charcoal</strong> or <strong>cholestyramine</strong>. It should be carried out within thirty minutes of ingestion. If they are used, gastric lavage must be done afterwards before using another agent. Acetaminophen blood levels can be estimated from a nomogram plot. In patients with high acetaminophen levels, <strong>intravenous N-acetylcysteine</strong> administration within 8 hours of ingestion is recommended. It helps in the replenishment of glutathione. It is partially effective even up to 36 hours. <strong>Liver transplantation</strong> is necessary if signs of hepatic failure continue despite therapy.\u00a0</p>\n<p>Other option(s):</p>\n<p>Option B: The nomogram used for <strong>vancomycin</strong> dosing is <strong>Matzke</strong> nomogram.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 35-year-old lady came to the OPD with complaints of occasional shock-like sensations down her spine and muscle spasms. T2 weighted MRI shows typical Dawson fingers and oligoclonal bands were detected in the CSF study.  Which of the following is approved for the treatment of her condition?",
    "choices": [
      {
        "id": 1,
        "text": "Interferon alpha"
      },
      {
        "id": 2,
        "text": "Interferon beta"
      },
      {
        "id": 3,
        "text": "Interferon gamma"
      },
      {
        "id": 4,
        "text": "Infliximab"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The given scenario is suggestive of <strong>multiple sclerosis.&nbsp;</strong><strong>Interferon beta</strong> is approved for use in this condition. It reduces the frequency of attacks in relapsing-remitting multiple sclerosis.</p>\n<p>The probable mechanisms of action of interferon-beta are:</p>\n<ul>\n<li>Immune modulation and a decrease in T cell proliferation.</li>\n<li>Limiting the entry of T cells into CNS.</li>\n<li>Reducing pro-inflammatory and increasing regulatory cytokines.</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "In a patient on lithium therapy for acute mania, what is considered the therapeutic range of serum lithium in mEq/L?",
    "choices": [
      {
        "id": 1,
        "text": "0.4 - 0.8"
      },
      {
        "id": 2,
        "text": "0.6 - 1.0"
      },
      {
        "id": 3,
        "text": "0.8 - 1.2"
      },
      {
        "id": 4,
        "text": "1.5 - 2.0"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p><strong>0.8\u20131.2 mEq/L</strong> of serum lithium is the favoured therapeutic range for the treatment of <strong>acute</strong> manic or hypomanic patients.</p>\n<p><strong>0.5\u20130.8 mEq/L</strong>\u00a0is considered adequate and safer for <strong>long-term prophylaxis</strong>.</p>\n<p><strong>Lithium</strong> is a mood stabilizer with a very narrow therapeutic index and is the first line of management in <strong>bipolar</strong> <strong>disorder</strong>. It <strong>decreases</strong> the <strong>rate</strong> <strong>of</strong> <strong>suicide</strong> and is also used in <strong>depression</strong> with inadequate response to monotherapy and cases of recurrent depression.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient who was being treated for an arrhythmia presented with palpitations and chest discomfort. His ECG has been given below. Which of the following drugs would be least likely to cause this condition?",
    "choices": [
      {
        "id": 1,
        "text": "Quinidine"
      },
      {
        "id": 2,
        "text": "Sotalol"
      },
      {
        "id": 3,
        "text": "Procainamide"
      },
      {
        "id": 4,
        "text": "Lidocaine"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p>The ECG of this patient shows\u00a0<strong>wide QRS complexes </strong>and an<strong>\u00a0undulating baseline </strong>suggesting the diagnosis of\u00a0<strong>torsades de pointes</strong>. It is associated with\u00a0<strong>prolonged QT interval.\u00a0Lidocaine</strong> does not prolong the QT interval, hence, it is<strong> unlikely</strong> to cause torsades de pointes.\u00a0</p>\n<p><strong>Lidocaine</strong> belongs\u00a0to the <strong>class IB</strong> antiarrhythmic agent. It is considered to have the least arrhythmogenic potential among antiarrhythmic. QT interval is usually unaltered or slightly reduced with lidocaine use.</p>\n<p>Among the antiarrhythmics, class Ia and class III drugs prolong action potential duration and thus prolong QT interval and are also prone to cause Torsades de pointes.</p>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/73e78df307ab449686e7e18b7b145007.JPEG"
    ],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/b2b1e13fe6134e12b1862511d5f653abx1280x1424.JPEG"
    ]
  },
  {
    "text": "The following finding was seen on performing a DAT scan in a patient who presented with bradykinesia, rigidity, and tremors. Which of the following drugs could be used in the treatment of this condition?",
    "choices": [
      {
        "id": 1,
        "text": "Valbenazine"
      },
      {
        "id": 2,
        "text": "Benztropine"
      },
      {
        "id": 3,
        "text": "Dantrolene"
      },
      {
        "id": 4,
        "text": "Propranalol"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><span data-preserver-spaces=\"true\">The\u00a0</span><strong><span data-preserver-spaces=\"true\">DAT</span></strong>(Dopamine active transporter)<strong><span data-preserver-spaces=\"true\">scan</span></strong><span data-preserver-spaces=\"true\"> image shows a normal\u00a0</span><strong><span data-preserver-spaces=\"true\">comma-shaped</span></strong><span data-preserver-spaces=\"true\">\u00a0pattern of the striatal nuclei, which rules out degenerative parkinsonism, suggesting secondary parkinsonism such as\u00a0</span><strong><span data-preserver-spaces=\"true\">drug</span></strong><span data-preserver-spaces=\"true\">-</span><strong><span data-preserver-spaces=\"true\">induced</span></strong><span data-preserver-spaces=\"true\">\u00a0</span><strong><span data-preserver-spaces=\"true\">parkinsonism</span></strong><span data-preserver-spaces=\"true\">. Among the given options,\u00a0</span><strong><span data-preserver-spaces=\"true\">Benztropine</span></strong><span data-preserver-spaces=\"true\">\u00a0can be used for\u00a0</span><strong><span data-preserver-spaces=\"true\">drug-induced parkinsonism </span></strong><span data-preserver-spaces=\"true\">and it </span><span data-preserver-spaces=\"true\">is an </span><strong><span data-preserver-spaces=\"true\">anticholinergic.</span></strong></p>\n<p><span data-preserver-spaces=\"true\"><strong>Drug-induced parkinsonism</strong> is a condition caused by certain drugs having D2 antagonistic action (typical antipsychotics). The decrease in dopaminergic activity results in an\u00a0</span><strong><span data-preserver-spaces=\"true\">unbalanced cholinergic activity</span></strong><span data-preserver-spaces=\"true\">. Anticholinergics act by restoring balance.</span></p>\n<p><strong><span data-preserver-spaces=\"true\">Management of Drug-induced Parkinsonism</span></strong></p>\n<p><span data-preserver-spaces=\"true\">There are two approaches to managing drug-induced parkinsonism: avoidance or discontinuation of known causative medications and symptomatic treatment of parkinsonism.</span></p>\n<ol>\n<li><strong><span data-preserver-spaces=\"true\">Avoidance or discontinuation of the drug</span></strong><span data-preserver-spaces=\"true\">- The best way to treat drug-induced parkinsonism is to avoid using causative agents, especially in high-risk populations such as older adults. Unfortunately, this is not always possible, as some patients with psychosis need to be treated with antipsychotic agents.</span></li>\n<li><strong><span data-preserver-spaces=\"true\">Symptomatic treatment-</span></strong><span data-preserver-spaces=\"true\">\u00a0When the causative agent cannot be discontinued, lowered, or switched to an alternative drug, symptomatic treatment of parkinsonism may be considered like:</span></li>\n</ol>\n<ul>\n<li><strong><span data-preserver-spaces=\"true\">Anticholinergic -</span></strong><span data-preserver-spaces=\"true\">\u00a0Benztropine</span></li>\n<li><span data-preserver-spaces=\"true\">Amantadine</span></li>\n<li><span data-preserver-spaces=\"true\">Levodopa</span></li>\n</ul>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/fe43662bbbb94690a89bc30089d0cde3.JPEG"
    ],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/c349cba35a56473aaefe2164a2bd9990x242x160.JPEG"
    ]
  },
  {
    "text": "A 60-year-old female patient presented with the following finding. Her medical history includes hypertension for which she has been taking amlodipine for the past 3 months. Which of the following mechanisms is most likely to be responsible?",
    "choices": [
      {
        "id": 1,
        "text": "Decreased hydrostatic pressure in the lower extremities"
      },
      {
        "id": 2,
        "text": "Decreased intravascular oncotic pressure"
      },
      {
        "id": 3,
        "text": "Precapillary dilation and reflex post capillary constriction"
      },
      {
        "id": 4,
        "text": "Precapillary constriction and reflex post capillary dilation"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>The image shows<strong> pitting pedal edema</strong> in a hypertensive patient. <strong>Calcium channel blockers (CCBs)</strong> like <strong>amlodipine</strong> are most likely to be associated with peripheral edema.\u00a0CCB-induced peripheral edema occurs due to a disproportionate decrease in the\u00a0arteriolar resistance than in the venous circulation, resulting in increased\u00a0hydrostatic pressure in the precapillary circulation. This leads to a fluid shift\u00a0into the interstitial compartment causing edema.</p>\n<p>The frequency of CCB-induced peripheral edema is both <strong>drug-specific</strong> (i.e more potent drugs like amlodipine will be associated with higher rates of developing edema) and <strong>dose-dependent</strong> (i.e incidence of edema increases with an increase in drug dosage and chronicity of its usage). It is more common among <strong>females.</strong></p>\n<p>Treatment:</p>\n<ul>\n<li>Dose reduction</li>\n<li>Interclass switching of CCB - switch to non-dihydropyridines like verapamil, and diltiazem</li>\n<li>Addition of a venodilator - ACE inhibitor, ARBs, Nitrates</li>\n<li>Others - compression stockings, avoiding prolonged upright position</li>\n<li>Definitive treatment would be discontinuation of the CCB and switching to another class of antihypertensives</li>\n</ul>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/cda9af4abc9841378a0d07e6dee3b224.JPEG"
    ],
    "explanation_images": []
  },
  {
    "text": "A 66-year-old male presents with fatigue, weight loss and anorexia. On examination, generalised lymphadenopathy is seen. Peripheral smear showed smudge cells and increased lymphocytes. Which of the following antimetabolites is preferred in treating this condition?",
    "choices": [
      {
        "id": 1,
        "text": "5-Fluorouracil"
      },
      {
        "id": 2,
        "text": "Fludarabine"
      },
      {
        "id": 3,
        "text": "6-mercaptopurine"
      },
      {
        "id": 4,
        "text": "Azathioprine"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The clinical presentation of fatigue, weight loss, anorexia, generalized lymphadenopathy, and the presence of <strong>smudge</strong> <strong>cells</strong> on a peripheral smear suggest <strong>chronic lymphocytic leukaemia (CLL)</strong>. Smudge cells are characteristic of CLL. The preferred antimetabolite in this case is <strong>Fludarabine</strong>.</p>\n<p><strong>Fludarabine</strong> is a <strong>purine analogue</strong> and an antimetabolite commonly used in the treatment of <strong>CLL</strong>. It acts by <strong>inhibiting DNA synthesis</strong> in rapidly dividing cells, including malignant lymphocytes. It is the preferred choice in this scenario for managing CLL.</p>\n<p><strong>Chronic</strong> <strong>lymphocytic</strong> <strong>leukaemia</strong> (CLL) is associated with the deletions of 13q, 11q, 17q, and trisomy 12q. Lymph nodes are diffusely effaced by small lymphocytes with proliferation centres. The peripheral smear shows small round lymphocytes with scant cytoplasm and smudge cells as seen below.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": [
      "https://dhmbxeygs57ff.cloudfront.net/uploads/aebe207b9383439782344d945a2e3201x355x512.JPEG"
    ]
  },
  {
    "text": "Which of the following forms of iron may be preferred in a patient with CKD already being treated with darbepoietin?",
    "choices": [
      {
        "id": 1,
        "text": "Oral ferrous sulphate"
      },
      {
        "id": 2,
        "text": "Intravenous iron sucrose"
      },
      {
        "id": 3,
        "text": "Subcutaneous iron dextran"
      },
      {
        "id": 4,
        "text": "Intramuscular iron dextran"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The preferred form of<strong> iron</strong> in a patient with <strong>chronic kidney disease </strong>(CKD) already being treated with <strong>darbepoetin</strong> is <strong>intravenous iron sucrose</strong>.</p>\n<p>Patients with CKD, particularly those receiving erythropoiesis-stimulating agents like darbepoetin, often have i<strong>mpaired gastrointestinal absorption of iron</strong> and increased iron requirements. <strong>Intravenous</strong> <strong>iron</strong>, such as iron sucrose, is <strong>preferred</strong> because it <strong>bypasses</strong> the <strong>gastrointestinal</strong> <strong>tract</strong>, has better bioavailability, and replenishes iron stores more efficiently in CKD patients.</p>\n<p><strong>Oral </strong>iron, like <strong>ferrous sulfate</strong>, is generally <strong>less effective </strong>in CKD patients, and <strong>subcutaneous </strong>or<strong> intramuscular</strong> forms, like<strong> iron dextran</strong>, are <strong>less</strong> commonly used due to risks of <strong>adverse reactions</strong> and <strong>poor absorption</strong>.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "If a drug follows first-order kinetics, how much drug will remain at the end of 6 hours when a patient is given 300 mg drug of which 120 mg is excreted in 90 min?",
    "choices": [
      {
        "id": 1,
        "text": "44 mg"
      },
      {
        "id": 2,
        "text": "38 mg"
      },
      {
        "id": 3,
        "text": "64 mg"
      },
      {
        "id": 4,
        "text": "28 mg"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The amount of drug remaining in the body after 6 hours following an initial administration of 300mg of the drug is <strong>38mg</strong>.</p>\n<p>In first-order kinetics,<strong>\u00a0a constant fraction of the drug is excreted in a given time.</strong>\u00a0</p>\n<p>120 mg of 300 mg is excreted in 90 minutes ---&gt; 120/300 =\u00a0<strong>0.40</strong>\u00a0is eliminated\u00a0</p>\n<p>After 90 minutes; 300 mg-120 mg = 180 mg remains\u00a0</p>\n<p>The next 90 minutes (after 180 minutes) = 180 *\u00a00.4 = 72 mg is eliminated and 180-72 = 108 mg remains\u00a0</p>\n<p>The next 90 minutes (after 270 minutes) = 108 *\u00a00.4 = 43.2 mg is eliminated and 108-43.2 = 64.8 remains\u00a0</p>\n<p>The next 90 minutes (after 360 minutes) = 64.8 *\u00a00.4 = 25.92 mg is eliminated and 64.80-25.92 =\u00a0<strong>38.88 mg remains after 6 hours.\u00a0</strong></p>\n<p><strong>A simpler way to calculate\u00a0</strong></p>\n<ul>\n<li>2/5 fraction is excreted in 90 minutes\u00a0\u2192 3/5 remains after 90 minutes.</li>\n<li>6 hours (360 min) is 4 times of 90 minutes.</li>\n<li>So 300 * (3/5)(3/5)(3/5)(3/5) = 38.88 mg remains after 360 minutes\u00a0</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A young man is diagnosed with hypertension. His laboratory studies reveal hypokalemia and metabolic alkalosis. He says that his mother was also diagnosed with hypertension at a younger age. Genetic testing revealed the presence of a mutation in ENaC gene. Which of the following drugs is commonly used in the treatment of the given condition?",
    "choices": [
      {
        "id": 1,
        "text": "Furosemide"
      },
      {
        "id": 2,
        "text": "Spironolactone"
      },
      {
        "id": 3,
        "text": "Amiloride"
      },
      {
        "id": 4,
        "text": "Hydrochlorothiazide"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>The clinical, laboratory, and genetic features are suggestive of <strong>Liddle's syndrome</strong>. It occurs due to the increased function of epithelial sodium channels. <strong>Amiloride</strong> blocks these channels and is therefore commonly used in the treatment of Liddle's syndrome.</p>\n<p>Amiloride is a <strong>potassium-sparing diuretic</strong> that <strong>blocks epithelial sodium channels</strong> in collecting tubules. Therefore, it reduces sodium retention and potassium wasting.\u00a0Triamterene acts similar to amiloride. However, it is less potent and more toxic than amiloride.</p>\n<p>It is used to treat <strong>Liddle's syndrome</strong>, hypokalemia due to other diuretics, and lithium-induced polyuria. Its toxicity can cause hyperkalemic metabolic acidosis.</p>\n<p>Liddle's syndrome is an <strong>autosomal dominant</strong> condition that is caused due to the <strong>gain of function mutation in the ENaC gene</strong> which codes for the epithelial sodium channels present in the kidney. Due to increased sodium retention, patients present with hypertension and hypokalemic alkalosis. They have\u00a0<strong>normal aldosterone levels.</strong> They respond to treatment with <strong>amiloride.</strong></p>\n<p>Other options:</p>\n<p>Option A:<strong>\u00a0Furosemide</strong> is a loop diuretic and acts by <strong>inhibiting\u00a0Na<sup>+</sup>/K<sup>+</sup>/2Cl<sup>-</sup> transporter</strong> in the ascending loop of Henle. Therefore it is not used in the treatment of <strong>Liddle's syndrome.</strong> A condition that mimics overdose loop diuretic is Bartter's syndrome. This syndrome occurs due to a defect in the\u00a0<strong>Na<sup>+</sup>/K<sup>+</sup>/2Cl<sup>-</sup> transporter</strong> in the ascending loop of Henle. Patients will have\u00a0<strong>low blood pressure</strong>, <strong>polyuria, polydipsia</strong>, hypokalemic metabolic alkalosis, and normal to increased calcium excretion.\u00a0</p>\n<p>Option B: <strong>Spironolactone\u00a0</strong>is an aldosterone antagonist. Since the levels of aldosterone are normal in Liddle's syndrome, it cannot be used in the treatment of the condition. The toxicity of spironolactone can cause hyperkalemia and gynecomastia.</p>\n<p>Option D: <strong>Hydrochlorothiazide</strong> is a thiazide diuretic and acts by the <strong>inhibition of the Na<sup>+</sup>/Cl<sup>-</sup> transporter</strong> in the <strong>distal convoluted tubule.\u00a0</strong>Therefore it is not commonly used in the treatment of Liddle's syndrome.<strong>\u00a0</strong>A condition that mimics an overdose of thiazide diuretics is <strong>Gitelman syndrome.</strong> It is an autosomal recessive disease that causes a defect in the\u00a0<strong>Na<sup>+</sup>/Cl<sup>-</sup> transporter</strong> in the <strong>distal convoluted tubule.\u00a0</strong>Patients present with low blood pressure, hypokalemic metabolic alkalosis, hypomagnesemia, and <strong>hypocalciuria.</strong></p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Match the following pairs of drugs with their antidotes.",
    "choices": [
      {
        "id": 1,
        "text": "1-b, 2-d, 3-a, 4-c"
      },
      {
        "id": 2,
        "text": "1-b, 2-c, 3-a, 4-d"
      },
      {
        "id": 3,
        "text": "1-b, 2-a, 3-c, 4-d"
      },
      {
        "id": 4,
        "text": "1-b, 2-a, 3-d, 4-c"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Option B </strong>is<strong> correctly matched.</strong></p>\n<table style=\"height: 61px; width: 285px;\">\n<tbody>\n<tr>\n<td style=\"width: 121.367px; text-align: center;\"><strong>Drug\u00a0</strong></td>\n<td style=\"width: 135.414px; text-align: center;\"><strong>Antidote</strong></td>\n</tr>\n<tr>\n<td style=\"width: 121.367px;\"><strong>1</strong>. Heparin</td>\n<td style=\"width: 135.414px;\"><strong>b</strong>. Protamine sulfate</td>\n</tr>\n<tr>\n<td style=\"width: 121.367px;\"><strong>2</strong>. Dabigatran</td>\n<td style=\"width: 135.414px;\"><strong>c</strong>. Idarucizumab</td>\n</tr>\n<tr>\n<td style=\"width: 121.367px;\"><strong>3</strong>. Warfarin</td>\n<td style=\"width: 135.414px;\"><strong>a</strong>.\u00a0Vitamin K</td>\n</tr>\n<tr>\n<td style=\"width: 121.367px;\"><strong>4</strong>. Rivaroxaban</td>\n<td style=\"width: 135.414px;\"><strong>d</strong>. Andexanet alfa</td>\n</tr>\n</tbody>\n</table>\n<p><br />Heparin - Protamine sulfate(1-b) :</p>\n<p><strong>Protamine sulfate</strong> is indicated for the reversal of<strong> heparin overdose</strong>. It binds to <strong>long heparin molecules</strong> with high affinity and neutralizes anticoagulant activity. Therefore, it <strong>completely reverses</strong> the action of unfractionated heparin but only <strong>partially reverses the action</strong> of low-molecular-weight heparin (LMWH). It has no effect on fondaparinux.</p>\n<p>Dabigatran - Idarucizumab (2-c) :</p>\n<p><strong>Idarucizumab</strong>\u00a0is a monoclonal antibody that specifically acts as a <strong>reversal agent </strong>for<strong> dabigatran</strong>. It has a 350 times higher affinity for dabigatran than dabigatran for thrombin. Hence, it forms a complex with dabigatran, which is excreted by the kidneys.</p>\n<p>Warfarin - Vitamin K (3-a) :</p>\n<p><strong>Vitamin K</strong> is given orally as well as intravenously to treat <strong>warfarin toxicity</strong>. It causes the reversal of anticoagulation effects of warfarin by synthesis of vitamin K\u2013dependent coagulation factors (II, VII, IX, X).</p>\n<p>Rivaroxaban - Andexanet alfa (4-d) :</p>\n<p><strong>Andexanet alfa</strong> is a\u00a0recombinant analog of factor Xa and is used as a <strong>reversal agent</strong> for\u00a0<strong>oral factor Xa inhibitors</strong>\u00a0like rivaroxaban, edoxaban, and apixaban.\u00a0It rapidly reverses the action of these drugs and restores thrombin generation. It is given intravenously.</p>\n<p>Note:</p>\n<div>\n<p><strong>Ciraparantag\u00a0</strong>is considered a potential <strong>reversal agent agains</strong>t <strong>all direct </strong><strong>anticoagulants,\u00a0</strong>including dabigatran, rivaroxaban, apixaban, and edoxaban, as well as heparin and LMWH. This drug is in the early stages of development.</p>\n</div>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following drugs is most likely to produce the following adverse effect?",
    "choices": [
      {
        "id": 1,
        "text": "Carbamazepine"
      },
      {
        "id": 2,
        "text": "Tacrolimus"
      },
      {
        "id": 3,
        "text": "Cyclosporine"
      },
      {
        "id": 4,
        "text": "Lamotrigine"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>The given image shows <strong>gum hyperplasia</strong>, which is an adverse effect most likely produced by <strong>cyclosporine</strong>.</p>\n<p>Other drugs that cause gum hyperplasia are:</p>\n<ul>\n<li><strong>Phenytoin</strong></li>\n<li><strong>Calcium channel blockers</strong></li>\n</ul>\n<p>Cyclosporine is an <strong>immunomodulator</strong> that binds with the <strong>cyclophilin</strong> protein, and this complex <strong>inhibits</strong> the <strong>calcineurin</strong> activity. It decreases T-cell activation and is useful in T-cell-mediated transplant rejection. It is useful in autoimmune conditions like rheumatoid arthritis, psoriasis, uveitis, Behcet's disease, atopic dermatitis, inflammatory bowel disease, nephrotic syndrome, etc. The major adverse effects are as follows:</p>\n<ul>\n<li><strong>Hirsutism</strong></li>\n<li><strong>Gum hyperplasia</strong></li>\n<li><strong>Nephrotoxicity</strong></li>\n<li><strong>Hepatotoxicity</strong></li>\n<li><strong>Hypertension</strong></li>\n<li>Hyperlipidemia</li>\n<li>Hyperglycemia</li>\n<li>Hyperuricemia</li>\n<li>Altered mental status, seizures</li>\n</ul>\n<p>Other options:</p>\n<p>Option A: <strong>Carbamazepine</strong> is an antiepileptic agent used in the treatment of generalised tonic-clonic seizures, focal seizures, trigeminal and glossopharyngeal neuralgias, bipolar disorder, and nephrogenic diabetes insipidus. The main adverse events are <strong>hepatotoxicity,</strong> <strong>dilutional hyponatremia, </strong>hypersensitivity reactions, aplastic anaemia, and agranulocytosis.</p>\n<p>Option B: <strong>Tacrolimus</strong> is a macrolide antibiotic that binds to <strong>FKBP-12</strong> protein (similar to cyclophilin) and <strong>inhibits calcineurin</strong> activity. It is indicated in the prophylaxis of solid-organ allograft rejection. Some of the adverse effects include <strong>nephrotoxicity, neurotoxicity</strong>, hypertension, and hyperglycemia.</p>\n<p>Option D: <strong>Lamotrigine</strong> is an antiepileptic agent used in focal and generalised tonic-clonic seizures and Lennox Gestaut syndrome. The adverse effects include <strong>Stevens-Johnson syndrome</strong>, dizziness, ataxia, and double vision.</p>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/ddeeb99a9e674b1086961125676f7764.JPEG"
    ],
    "explanation_images": []
  },
  {
    "text": "A patient who has undergone renal transplantation is started on mycophenolate mofetil as prophylaxis for transplant rejection. What is the mechanism of action of this drug?",
    "choices": [
      {
        "id": 1,
        "text": "Inhibition of calcineurin"
      },
      {
        "id": 2,
        "text": "Inhibition of mTOR"
      },
      {
        "id": 3,
        "text": "Inhibition of TNF-\u03b1"
      },
      {
        "id": 4,
        "text": "Inhibition of inosine monophosphate dehydrogenase"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p>The mechanism of action of <strong>mycophenolate mofetil </strong>is the <strong>inhibition of inosine monophosphate dehydrogenase</strong>.</p>\n<p><strong>Mycophenolate mofetil</strong> is a <strong>prodrug</strong> that is rapidly converted to <strong>mycophenolic acid</strong>. It is a <strong>selective</strong>, non-competitive, <strong>reversible inhibitor of inosine monophosphate dehydrogenase (IMPDH)</strong>, an important enzyme in the de novo pathway of guanine nucleotide synthesis in T and B lymphocytes. By inhibiting IMPDH, mycophenolate selectively suppresses lymphocyte proliferation, reducing the immune response against the transplanted organ. Hence, used in the prophylaxis of organ transplants.</p>\n<p>Other options</p>\n<p>Option A: <strong>Cyclosporine</strong> and <strong>tacrolimus</strong> act by <strong>inhibiting calcineurin</strong>. Cyclosporine is an immunomodulatory drug that inhibits calcineurin activity by forming a complex with cyclophilin, a cytoplasmic-receptor protein in target cells, forming a cyclosporine-cyclophilin complex. Tacrolimus is a calcineurin inhibitor that blocks FKBP 12. This immunophilin ultimately <strong>inhibits</strong> <strong>calcineurin</strong> phosphatase and exerts its actions.\u00a0</p>\n<p>Option B: <strong>Sirolimus</strong> is an antimetabolic and antiproliferative drug. It acts by forming a complex with an immunophilin called FKBP-12, inhibiting the mammalian target of rapamycin (<strong>mTOR</strong>). mTOR is a protein kinase that blocks cell cycle progression at the G1 phase to S phase transition. It is used in the prophylaxis of organ transplant rejection</p>\n<p>Option C:<strong> Infliximab</strong> is a chimeric IgG1 monoclonal antibody against <strong>TNF-\u03b1. </strong>It binds with high affinity to TNF-\u03b1 and prevents the cytokine from binding to its receptors.\u00a0</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A young patient presents with a persistent and painful penile erection. He had been taking sildenafil without proper medical consultation. Which of the following drugs can be given as an intracavernosal injection to this patient?",
    "choices": [
      {
        "id": 1,
        "text": "Phenylephrine"
      },
      {
        "id": 2,
        "text": "Oxymetazoline"
      },
      {
        "id": 3,
        "text": "Alprostadil"
      },
      {
        "id": 4,
        "text": "Papaverine"
      }
    ],
    "correct_choice_id": 1,
    "solution": "<p><strong>Intracavernous injection </strong>of\u00a0<strong>p</strong><strong>henylephrine</strong> can be given to this patient to relieve the priapism and prevent ischemic damage.</p>\n<p><strong>Priapism</strong> (sustained painful penile erection &gt;4 hours) is a common and serious side effect of <strong>s</strong><strong>ildenafil.</strong>\u00a0Other causes of priapism include <strong>trazodone</strong> (serotonin receptor antagonist) and cantharidin from <strong>Spanish fly</strong>.</p>\n<p>Phenylephrine is\u00a0an<strong>\u00a0\u03b1<sub>1</sub> selective adrenergic agonist. </strong>It serves as a <strong>vasoconstrictor\u00a0</strong>of the arterioles and reduces the engorgement of cavernosal space, thus <strong>reversing priapism</strong>.</p>\n<p>Phenylephrine is a pure\u00a0<strong>\u03b1<sub>1\u00a0</sub></strong><strong>adrenergic agonist.\u00a0</strong>By means of acting on\u00a0<strong>\u03b11 receptors</strong>, it increases the\u00a0<strong>peripheral arterial resistance,</strong>\u00a0and decreases the capacity of\u00a0<strong>venous capacitance vessels,\u00a0</strong>leading to an increased venous return to the heart. There is a\u00a0<strong>baroreceptor reflex-mediated</strong>\u00a0increase in vagal tone due to which there is marked\u00a0<strong>bradycardia</strong>. However, due to increased venous return, <strong>stroke volume remains high</strong> and so does the cardiac output.</p>\n<p>Other options:</p>\n<p>Option B: <strong>Oxymetazoline</strong> is a vasoconstrictor used in <strong>nasal congestion</strong> and sinus surgeries. It is available generally as a <strong>nasal spray</strong>.</p>\n<p>Options C and D: <strong>Papaverine</strong> (with or without <strong>phentolamine</strong>) and <strong>alprostadil</strong> are used in the <strong>treatment of erectile dysfunction</strong>.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Your senior asks you to administer a selective COX-2 inhibitor intravenously to a patient for post-op analgesia. Which of the following will you choose?",
    "choices": [
      {
        "id": 1,
        "text": "Celecoxib"
      },
      {
        "id": 2,
        "text": "Etoricoxib"
      },
      {
        "id": 3,
        "text": "Rofecoxib"
      },
      {
        "id": 4,
        "text": "Parecoxib"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><strong>Parecoxib </strong>is chosen as it is the only <strong>injectable COX-2 selective drug\u00a0</strong>among the given options.</p>\n<p>It is a\u00a0<strong>water-soluble</strong>\u00a0<strong>prodrug</strong> of <strong>valdecoxib</strong>. It is effective in the perioperative period when oral medications are not indicated.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Acetazolamide is used in all the following conditions except",
    "choices": [
      {
        "id": 1,
        "text": "Epilepsy"
      },
      {
        "id": 2,
        "text": "Diuretic resistance"
      },
      {
        "id": 3,
        "text": "Familial periodic paralysis"
      },
      {
        "id": 4,
        "text": "Chronic kidney disease"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p><span style=\"font-family: arial, helvetica, sans-serif;\"><strong>Acetazolamide </strong>is used in all the above conditions<strong> except chronic kidney disease</strong> (CKD).</span></p>\n<p><span style=\"font-family: arial, helvetica, sans-serif;\">Acetazolamide is not typically used in patients with chronic kidney disease (CKD), especially those with advanced kidney disease. Since acetazolamide relies on <strong>renal excretion</strong>, impaired kidney function can lead to drug accumulation and increase the risk of metabolic acidosis, which is already a concern in CKD patients. Additionally, its diuretic effect is weak compared to other diuretics and is generally not helpful in managing CKD-related issues. Thus, acetazolamide is generally avoided in CKD patients due to potential complications and limited benefit.</span></p>\n<p><span style=\"font-family: arial, helvetica, sans-serif;\">Therapeutic uses of acetazolamide:</span></p>\n<ul>\n<li><span style=\"font-family: arial, helvetica, sans-serif;\">Glaucoma</span></li>\n<li><span style=\"font-family: arial, helvetica, sans-serif;\"><strong>Epilepsy</strong></span></li>\n<li><span style=\"font-family: arial, helvetica, sans-serif;\">Altitude sickness</span></li>\n<li><span style=\"font-family: arial, helvetica, sans-serif;\"><strong>Diuretic resistance</strong></span></li>\n<li><span style=\"font-family: arial, helvetica, sans-serif;\">Metabolic alkalosis</span></li>\n<li><span style=\"font-family: arial, helvetica, sans-serif;\"><strong>Familial periodic paralysis</strong></span></li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 50-year-old male patient was diagnosed with pulmonary artery hypertension. He was prescribed an endothelin receptor antagonist for the management of the same. After starting the drug, he developed nasal congestion and pharyngitis. Which of the following drugs was prescribed?",
    "choices": [
      {
        "id": 1,
        "text": "Epoprostenol"
      },
      {
        "id": 2,
        "text": "Bosentan"
      },
      {
        "id": 3,
        "text": "Inhaled nitric oxide (NO)"
      },
      {
        "id": 4,
        "text": "Sildenafil"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>The drug prescribed is\u00a0<strong>bosentan</strong>.\u00a0</p>\n<p>The clinical scenario of the development of <strong>nasal congestion and pharyngitis</strong> after administration of an <strong>endothelin receptor antagonis</strong>t given for the treatment of pulmonary artery hypertension suggests that the drug prescribed is bosentan.</p>\n<ul>\n<li><strong>ET</strong><sub><strong>A</strong> -\u00a0</sub>This receptor is localized on the<strong> pulmonary artery smooth muscle cell</strong>. It is a <strong>G-protein coupled receptor\u00a0</strong>and acts via the <strong>IP<sub>3</sub>-DAG</strong> pathway elevating cytosolic Ca<sup>2+\u00a0</sup>thus causing <strong>vasoconstriction</strong>.</li>\n<li><strong>ET<sub>B</sub></strong> - This receptor is present on the pulmonary artery smooth muscle cell and <strong>endothelial cell</strong>. It is a\u00a0<strong>G-protein coupled receptor\u00a0</strong>and on activation, the\u00a0ET<sub>B\u00a0</sub>receptors on the endothelial cells increase the production of <strong>PGI<sub>2,\u00a0</sub>NO and inhibit ET-1 production.</strong></li>\n</ul>\n<p>Endothelin receptor antagonists act by either non-selectively inhibiting both endothelin receptors or by selectively inhibiting\u00a0ET<sub>A </sub>receptors only. The <strong>nonselective </strong>endothelin receptor antagonists are\u00a0<strong>bosentan\u00a0</strong>and\u00a0<strong>macitentan.\u00a0</strong>The <strong>selective</strong> endothelin receptor antagonists are\u00a0<strong>ambrisentan\u00a0</strong>and\u00a0<strong>sitaxsentan.\u00a0</strong><strong>Sitaxsentan</strong> is the <strong>most selective</strong>\u00a0<strong>ET<sub>A</sub></strong> receptor <strong>antagonist.</strong>\u00a0These drugs are predominantly used in the treatment of pulmonary artery hypertension.</p>\n<p>Side effects:</p>\n<ul>\n<li><strong>Headache</strong></li>\n<li><strong>Pulmonary edema</strong></li>\n<li><strong>Nasal congestion</strong>/<strong>pharyngitis</strong></li>\n<li><strong>Hepatotoxicity -\u00a0</strong> needs monitoring and\u00a0<strong>contraindicated\u00a0</strong>in patients with mild-moderate liver disease.</li>\n<li><strong>Teratogenic</strong> -\u00a0<strong>contraindicated\u00a0</strong>in\u00a0<strong>pregnancy</strong>.</li>\n</ul>\n<p>Other options:</p>\n<p>Option A- <strong>Epoprostenol</strong> is a <strong>synthetic\u00a0PGI</strong><sub><strong>2</strong>,\u00a0</sub>It acts by inhibiting myosin light chain kinase and activating K+ channels. It is the mainstay of treatment of pulmonary artery hypertension, particularly in advanced stages. The important side effects include\u00a0<strong>myalgia, jaw pain, nausea, flushing, and systemic hypotension.</strong></p>\n<p>Option C- <strong>Inhaled NO</strong>\u00a0acts by <strong>activation</strong> of<strong> soluble guanylyl cyclase</strong> \u2192 activates cyclic guanosine monophosphate (cGMP). An important side effect is <strong>methemoglobinemia.</strong></p>\n<p>Option D- <strong>Sildenafil</strong> acts by competitive <strong>inhibition</strong> of <strong>phosphodiesterase</strong>\u00a0<strong>5</strong> (PDE5). Important side effects are\u00a0<strong>headache, flushing\u00a0</strong>and\u00a0<strong>blue-green vision</strong>.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A patient is given a nicotinic receptor antagonist as a muscle relaxant. Which of the following accurately describes the drug given postoperatively to recover from muscle weakness?",
    "choices": [
      {
        "id": 1,
        "text": "Lipid-soluble reversible inhibitor of acetylcholinesterase"
      },
      {
        "id": 2,
        "text": "Water-soluble reversible inhibitor of acetylcholinesterase"
      },
      {
        "id": 3,
        "text": "Lipid-soluble irreversible inhibitor of acetylcholinesterase"
      },
      {
        "id": 4,
        "text": "Water-soluble irreversible inhibitor of acetylcholinesterase"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Neostigmine </strong>is the drug given postoperatively to recover from muscle weakness, which is a <strong>water-soluble reversible inhibitor of acetylcholinesterase</strong>.</p>\n<p><strong>Non-depolarizing muscle relaxants</strong> (NDMRs) act mainly by the <strong>competitive antagonism</strong> of nicotinic (Nm) receptors. <strong>Neostigmine</strong> inhibits acetylcholinesterase and inhibits the degradation of acetylcholine. The increased accumulation of undegraded acetylcholine can effectively compete with NDMRs, thereby displacing them from the site and antagonising their effects.</p>\n<p>Neostigmine is a <strong>quaternary ammonium compound</strong> that results in a permanently charged molecule that <strong>cannot cross the blood-brain barrier</strong>, so its effects are limited to peripheral tissues.\u00a0</p>\n<p>Neostigmine is most commonly used in the management of myasthenia gravis.\u00a0</p>\n<p>Other therapeutic uses of neostigmine:\u00a0</p>\n<ul>\n<li>Postoperative decurarization</li>\n<li>Cobra bite</li>\n<li>Belladonna poisoning</li>\n<li>Postoperative paralytic ileus</li>\n</ul>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A 24-year-old man presents at your outpatient department with a productive cough. You have decided to prescribe him expectorants. Which of the following is an expectorant?",
    "choices": [
      {
        "id": 1,
        "text": "Acetylcysteine"
      },
      {
        "id": 2,
        "text": "Guaifenesin"
      },
      {
        "id": 3,
        "text": "Bromhexine"
      },
      {
        "id": 4,
        "text": "Dornase alfa"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p>Among the given drugs, <strong>guaifenesin</strong> is an <strong>expectorant\u00a0</strong>used in productive cough.</p>\n<p><strong>Guaifenesin</strong> is an <strong>expectorant</strong> that helps to <strong>thin </strong>and<strong> loosen mucus</strong>, making it <strong>easier to clear</strong> from the airways through coughing.</p>\n<p>Other options:</p>\n<p>Option A: <strong>Acetylcysteine</strong> is a <strong>mucolytic </strong>agent that reduces the viscosity of mucus, but is not an expectorant.</p>\n<p>Option C: <strong>Bromhexine</strong> is also a <strong>mucolytic </strong>agent<strong> </strong>and<strong> </strong>is<strong> </strong>not an expectorant.</p>\n<p>Option D: <strong>Dornase alfa</strong> is used to <strong>break down DNA in mucus</strong>, primarily for patients with cystic fibrosis, and is not classified as an expectorant.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "A drug is instilled into the right eye of the rabbit, and the left eye is used as the control. The findings obtained after some time are shown in the table and image given below.",
    "choices": [
      {
        "id": 1,
        "text": "Cocaine"
      },
      {
        "id": 2,
        "text": "Physostigmine"
      },
      {
        "id": 3,
        "text": "Pilocarpine"
      },
      {
        "id": 4,
        "text": "Atropine"
      }
    ],
    "correct_choice_id": 4,
    "solution": "<p>On instillation of the drug, there is <strong>mydriasis</strong> in the eye and <strong>loss of light reflex</strong>. The drug is likely to be <strong>atropine</strong>. It is an anticholinergic agent. It causes mydriasis, cycloplegia, loss of light reflex, and impaired accommodation.</p>\n<p>Autonomic supply of the eye:</p>\n<p>The <strong>radial muscle</strong> of the iris is controlled by\u00a0<strong>\u03b1</strong><span class=\"s1\"><strong>1 adrenergic receptor</strong>. Stimulation of this receptor causes <strong>mydriasis.\u00a0</strong></span></p>\n<p><span class=\"s1\">The<strong> sphincter muscle </strong>of the iris is controlled by the\u00a0</span><strong>M<span class=\"s1\">3 and</span>\u00a0M</strong><span class=\"s1\"><strong>2 cholinergic receptors.</strong> Stimulation of these receptors causes <strong>miosis.</strong></span></p>\n<p><span class=\"s1\"><strong>The ciliary muscle </strong>is supplied by the\u00a0</span><strong>\u03b2</strong><span class=\"s1\"><strong>2</strong> adrenergic receptors as well as\u00a0</span><strong>M<span class=\"s1\">3 and</span>\u00a0M</strong><span class=\"s1\"><strong>2</strong> cholinergic receptors. The\u00a0<strong>\u03b22</strong>\u00a0receptors cause relaxation of the ciliary muscle, which helps in <strong>far vision,</strong> while\u00a0<strong>M3 and M2\u00a0</strong>receptors cause contraction of the ciliary muscle, which helps in\u00a0<strong>near vision.</strong></span></p>\n<p><span class=\"s1\"><strong>Lacrimal glands are supplied by the\u00a0</strong></span>\u03b1 receptors and M3 and M2 receptors. They increase lacrimal secretion.</p>\n<p>Effects of various drugs on the eye</p>\n<table style=\"height: 217px; width: 733px;\">\n<tbody>\n<tr>\n<td style=\"width: 134px; text-align: center;\"><strong>Class</strong></td>\n<td style=\"width: 134px; text-align: center;\"><strong>Muscarinic receptor antagonist</strong></td>\n<td style=\"width: 134px; text-align: center;\"><strong>Cholinesterase inhibitors</strong></td>\n<td style=\"width: 135px; text-align: center;\"><strong>Muscarinic receptor agonist</strong></td>\n<td style=\"width: 135px; text-align: center;\"><strong>Adrenergic agonist</strong></td>\n<td style=\"width: 162px; text-align: center;\"><strong>Local anesthetic</strong></td>\n</tr>\n<tr>\n<td style=\"width: 134px;\">Drugs</td>\n<td style=\"width: 134px;\"><strong>Atropine</strong>, homatropine, Scopalamine, Tropicamide</td>\n<td style=\"width: 134px;\"><strong>Physostigmine</strong>, neostigmine, pyridostigmine, organophosphorus compounds, etc</td>\n<td style=\"width: 135px;\"><strong>Pilocarpine</strong></td>\n<td style=\"width: 135px;\">Epinephrine</td>\n<td style=\"width: 162px;\"><strong>Cocaine</strong></td>\n</tr>\n<tr>\n<td style=\"width: 134px;\">Mechanism of action in the eye</td>\n<td style=\"width: 134px;\"><strong>Blocks M3 and M2</strong> receptors</td>\n<td style=\"width: 134px;\"><strong>Stimulates M3 and M2</strong> receptors</td>\n<td style=\"width: 135px;\"><strong>Stimulates M3 and M2</strong> receptors in the eye</td>\n<td style=\"width: 135px;\"><strong>Stimulates\u00a0\u03b1</strong><span class=\"s1\"><strong>1 </strong>receptor\u00a0 in the eye</span></td>\n<td style=\"width: 162px;\"><strong>Blocks sodium channel</strong> and blocks <strong>norepinephrine transporter</strong></td>\n</tr>\n<tr>\n<td style=\"width: 134px;\">Effect on iris</td>\n<td style=\"width: 134px;\">Mydriasis</td>\n<td style=\"width: 134px;\">Miosis</td>\n<td style=\"width: 135px;\">Miosis</td>\n<td style=\"width: 135px;\">Mydriasis</td>\n<td style=\"width: 162px;\">Mydriasis</td>\n</tr>\n<tr>\n<td style=\"width: 134px;\">Corneal reflex</td>\n<td style=\"width: 134px;\">Present</td>\n<td style=\"width: 134px;\">Present</td>\n<td style=\"width: 135px;\">Present</td>\n<td style=\"width: 135px;\">Present</td>\n<td style=\"width: 162px;\">Absent</td>\n</tr>\n<tr>\n<td style=\"width: 134px;\">Light reflex</td>\n<td style=\"width: 134px;\"><strong>Absent</strong></td>\n<td style=\"width: 134px;\">Present</td>\n<td style=\"width: 135px;\">Present</td>\n<td style=\"width: 135px;\">Present</td>\n<td style=\"width: 162px;\">Present</td>\n</tr>\n<tr>\n<td style=\"width: 134px;\">Lacrimal secretions</td>\n<td style=\"width: 134px;\">Decreased</td>\n<td style=\"width: 134px;\">Increased</td>\n<td style=\"width: 135px;\">Increased</td>\n<td style=\"width: 135px;\">\u00a0Increased</td>\n<td style=\"width: 162px;\">---</td>\n</tr>\n</tbody>\n</table>",
    "explanation_video": "",
    "question_images": [
      "https://cdn1.dailyrounds.org/uploads/38cc05b0933e4f65a83a650431d5c197.JPEG"
    ],
    "explanation_images": []
  },
  {
    "text": "A 60-year-old male patient who is a known case of familial hypercholesterolemia was prescribed alirocumab. It helps in lowering lipid by __________.",
    "choices": [
      {
        "id": 1,
        "text": "PCSK-7 inhibition"
      },
      {
        "id": 2,
        "text": "PCSK-9 inhibition"
      },
      {
        "id": 3,
        "text": "PCSK-6 inhibition"
      },
      {
        "id": 4,
        "text": "PCSK-8 inhibition"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p class=\"p1\"><strong>Alirocumab</strong> helps in lowering lipids by&nbsp;<strong>PCSK-9 inhibition. </strong></p>\n<p class=\"p1\">It<strong>&nbsp;</strong>is a monoclonal antibody that binds to<strong> proprotein convertase subtilisin Kexin type 9 </strong>(PCSK-9).&nbsp;<strong>PCSK-9 is a protease</strong> involved in the <strong>degradation </strong>of <strong>LDL receptors, which results&nbsp;</strong>in higher plasma LDL concentrations. Alirocumab binds to free PCSK-9, thereby interfering with its binding to the LDL receptor, leading to increased liver clearance of LDL from the circulation and lower serum LDL levels.</p>\n<p class=\"p1\"><strong>Alirocumab</strong> and <strong>evolocumab&nbsp;</strong>are 2 FDA-approved PCSK9 inhibitors. It is used as adjunctive therapy in patients with<strong>&nbsp;familial hypercholesterolemia </strong>or established&nbsp;<strong>atherosclerotic cardiovascular disease</strong>, in whom the maximum tolerated statin dose is not able to achieve target LDL reduction.</p>\n<p class=\"p1\">It is administered as <strong>subcutaneous injections</strong> every 2 weeks or once monthly depending on the indication.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "The urine of the patient taking indapamide will have:",
    "choices": [
      {
        "id": 1,
        "text": "1"
      },
      {
        "id": 2,
        "text": "2"
      },
      {
        "id": 3,
        "text": "3"
      },
      {
        "id": 4,
        "text": "4"
      }
    ],
    "correct_choice_id": 3,
    "solution": "<p>The correct option is option C i.e. the urine will have<strong> increased</strong> levels of <strong>chloride, magnesium</strong>, and <strong>potassium</strong> and <strong>decreased</strong> levels of <strong>urea</strong>.\u00a0</p>\n<p><strong>Indapamide</strong> is a<strong> thiazide</strong> diuretic that can cause increased loss of chloride, potassium, and magnesium and decreased excretion of urea in urine. Thus resulting in <strong>hypokalemia, hyperuricemia, hypomagnesemia</strong>, and <strong>hypercalcemia</strong>\u00a0as adverse effects.</p>\n<p><strong>Thiazides</strong> act on the <strong>distal convoluted tubule</strong> (DCT). They block the <strong>Na<sup>+</sup>/Cl<sup>-</sup> co-transporter</strong> in the DCT. This results in the loss of sodium, chloride, and water contributing to the diuretic effect.</p>\n<p>The diuretic effect of thiazide leads to <strong>decreased osmotic pressure</strong> due to the loss of Na<sup>+</sup>, Cl<sup>-</sup>, and water leading to compensatory reabsorption of uric acid thus resulting in <strong>hyperuricemia.</strong></p>\n<p>The intracytoplasmic Na<sup>+</sup> concentration also decreases due to the blockade of the co-transporter. To compensate, the <strong>Na<sup>+</sup>/Ca<sup>2+</sup> exchanger</strong> pumps sodium from the systemic circulation into the epithelial cells in exchange for calcium. The declining calcium levels inside the cell will draw more calcium from the lumen into the systemic circulation. This results in <strong>hypercalcemia.</strong> There is also <strong>increased loss</strong> of <strong>Mg<sup>2+</sup></strong>, <strong>K<sup>+</sup></strong>, and<strong> H<sup>+</sup></strong>.</p>\n<p>Thiazides are the diuretic of choice for <strong>uncomplicated hypertension</strong>.</p>\n<p>The advantages of thiazide as an antihypertensive are:</p>\n<ul>\n<li>It can be given as once a day dose and has a flat dose-response curve</li>\n<li>Decreased incidence of postural hypotension and relative freedom from CNS side effects</li>\n<li>No tolerance</li>\n<li>No fluid retention</li>\n<li>Decreased risk of <strong>osteoporotic fractures</strong> due to its <strong>hypocalciuric</strong> action</li>\n<li>Low cost</li>\n<li>Effectiveness in <strong>isolated systolic hypertension</strong></li>\n</ul>\n<p>Thiazides are ineffective both as antihypertensive and diuretic in patients with chronic renal failure.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  },
  {
    "text": "Which of the following is incorrect regarding chlorpheniramine?",
    "choices": [
      {
        "id": 1,
        "text": "It belongs to first-generation antihistamines"
      },
      {
        "id": 2,
        "text": "It does not cross the blood-brain barrier"
      },
      {
        "id": 3,
        "text": "It has anticholinergic action"
      },
      {
        "id": 4,
        "text": "It is used in pruritus"
      }
    ],
    "correct_choice_id": 2,
    "solution": "<p><strong>Chlorpheniramine</strong> <strong>crosses </strong>the <strong>blood-brain barrier</strong>. Hence, <strong>option B</strong> is <strong>incorrect.</strong></p>\n<p>Chlorpheniramine is a <strong>first-generation antihistamine</strong>. First-generation antihistamines are <strong>lipophilic</strong> and hence are <strong>sedative</strong> because of their ability to cross the blood-brain barrier. It also has <strong>anticholinergic action</strong>, which can cause side effects like dry mouth and blurred vision.\u00a0</p>\n<p><strong>First-generation antihistamines</strong> such as <strong>chlorpheniramine,</strong> promethazine, dimenhydrinate diphenhydramine, cyclizine, and meclizine are effective in controlling nausea and vomiting in<strong> motion sickness</strong>. <strong>First</strong>-<strong>generation</strong> <strong>antihistamines</strong> have a strong <strong>sedative</strong> property and also have an <strong>antimuscarinic</strong> function. Whereas <strong>second</strong>-<strong>generation</strong> antihistamines like cetirizine and fexofenadine are <strong>ineffective</strong> in the treatment of <strong>motion</strong> <strong>sickness</strong>. Second-generation antihistamines are <strong>less sedative</strong> because of less central nervous system penetration and do not block autonomic receptors.</p>",
    "explanation_video": "",
    "question_images": [],
    "explanation_images": []
  }
];
        let quizName = 'Pharmacology Test';
        const quizFilename = 'pharmacology-test-d52ece43.html';
        let hierarchy = ["Marrow", "NEET PG Test Series Subject Wise", "Year 2024 - 25"];
        
        // Handle Custom Quiz Loading
        if (window.location.pathname.endsWith('custom_quiz.html')) {
            const customData = JSON.parse(localStorage.getItem('customQuizData'));
            if (customData) {
                questionsData = customData.questions;
                quizName = customData.name;
                hierarchy = customData.hierarchy;
                document.title = quizName + ' - Brain And Scalpel';
                document.getElementById('totalQuestions').textContent = questionsData.length;
                document.getElementById('quizHierarchy').textContent = hierarchy.join(' > ');
            }
        }

        let currentQuestionIndex = 0;
        let selectedOption = null;
        let currentMode = 'study';
        let timer = null;
        let timeRemaining = 0;
        let questionStartTime = Date.now();
        let quizStartTime = Date.now();
        let isQuizCompleted = false;
        
        let questionStates = new Array(questionsData.length).fill(null).map(() => ({
            status: 'not_attempted',
            bookmarked: false,
            markedForReview: false,
            selectedAnswer: null,
            timeSpent: 0
        }));
        
        let stats = {
            correctAnswers: 0,
            incorrectAnswers: 0,
            totalAttempted: 0,
            totalTime: 0,
            notAttempted: questionsData.length
        };

        // --- NEW: History Management ---
        function saveProgress() {
            if (isQuizCompleted) return; // Don't save after completion
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            userHistory[quizFilename] = {
                questionStates,
                stats,
                currentQuestionIndex,
                currentMode,
                status: 'incomplete',
                lastSeen: new Date().toISOString()
            };
            localStorage.setItem('userHistory', JSON.stringify(userHistory));
        }

        function loadProgress() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            const savedState = userHistory[quizFilename];
            if (savedState) {
                questionStates = savedState.questionStates;
                stats = savedState.stats;
                currentQuestionIndex = savedState.currentQuestionIndex;
                currentMode = savedState.currentMode;
                console.log('Progress loaded.');
                return true;
            }
            return false;
        }

        function clearProgress() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            if(userHistory[quizFilename]) {
                delete userHistory[quizFilename];
                localStorage.setItem('userHistory', JSON.stringify(userHistory));
                console.log('Previous progress cleared.');
            }
        }

        function markQuizAsCompleted() {
            const userHistory = JSON.parse(localStorage.getItem('userHistory')) || {};
            const totalQuestions = questionsData.length;
            const correct = stats.correctAnswers || 0;
            
            userHistory[quizFilename] = {
                score: correct,
                total: totalQuestions,
                status: 'completed',
                completedOn: new Date().toISOString()
            };
            localStorage.setItem('userHistory', JSON.stringify(userHistory));
        }
        // --- End of History Management ---

        const urlParams = new URLSearchParams(window.location.search);
        const startAt = parseInt(urlParams.get('startAt'));
        const resume = urlParams.get('resume') === 'true';

        function goBack() {
            if (!isQuizCompleted) saveProgress(); // Save progress before leaving
            window.location.href = document.referrer || 'index.html';
        }

        function selectMode(mode) {
            currentMode = mode;
            document.getElementById('modeModal').style.display = 'none';
            initializeQuiz();
        }

        function initializeQuiz() {
            quizStartTime = Date.now();
            
            const bookmarkBtn = document.getElementById('bookmarkBtn');
            const markReviewBtn = document.getElementById('markReviewBtn');
            const testModeReviewLegend = document.getElementById('testModeReviewLegend');
            const isTestMode = currentMode === 'test' || currentMode === 'timed_exam';
            
            document.getElementById('statsBar').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('studyModeLegend').style.display = isTestMode ? 'none' : 'block';
            document.getElementById('testModeLegend').style.display = isTestMode ? 'block' : 'none';
            document.getElementById('submitSection').style.display = isTestMode ? 'block' : 'none';
            bookmarkBtn.style.display = isTestMode ? 'none' : 'flex';
            markReviewBtn.style.display = isTestMode ? 'flex' : 'none';
            testModeReviewLegend.style.display = isTestMode ? 'flex' : 'none';
            
            if (currentMode === 'timed_study' || currentMode === 'timed_exam') {
                document.getElementById('timerContainer').classList.remove('hidden');
            }
            
            if (!isNaN(startAt) && startAt >= 0 && startAt < questionsData.length) {
                currentQuestionIndex = startAt;
            }

            loadBookmarkedQuestions();
            generateQuestionNav();
            updateStats();
            displayQuestion();
        }

        function generateQuestionNav() {
            const nav = document.getElementById('questionNav');
            nav.innerHTML = '';
            
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.createElement('button');
                btn.textContent = i + 1;
                btn.className = 'w-8 h-8 text-sm font-medium rounded transition-all duration-200';
                btn.onclick = () => jumpToQuestion(i);
                btn.id = `navBtn_${i}`;
                nav.appendChild(btn);
            }
            
            updateQuestionNav();
        }

        function updateQuestionNav() {
            for (let i = 0; i < questionsData.length; i++) {
                const btn = document.getElementById(`navBtn_${i}`);
                const state = questionStates[i];
                let className = '';
                
                if (i === currentQuestionIndex) {
                    className = 'nav-btn-current';
                } else if (state.bookmarked) {
                    className = 'nav-btn-bookmarked';
                } else if (state.markedForReview) {
                    className = 'nav-btn-marked-review';
                } else if (currentMode === 'study' || currentMode === 'timed_study') {
                    if (state.status === 'correct') className = 'nav-btn-correct';
                    else if (state.status === 'incorrect') className = 'nav-btn-incorrect';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                } else {
                    if (state.selectedAnswer !== null) className = 'nav-btn-answered';
                    else className = 'nav-btn-not-attempted hover:bg-white hover:bg-opacity-20';
                }
                btn.className = `w-8 h-8 text-sm font-medium rounded ${className}`;
            }
        }

        function jumpToQuestion(index) {
            if (index >= 0 && index < questionsData.length) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex = index;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            }
        }

        function updateStats() {
            if (currentMode === 'study' || currentMode === 'timed_study') {
                document.getElementById('correctCount').textContent = stats.correctAnswers;
                document.getElementById('incorrectCount').textContent = stats.incorrectAnswers;
                document.getElementById('totalAttempted').textContent = stats.totalAttempted;
                
                const accuracy = stats.totalAttempted > 0 
                    ? Math.round((stats.correctAnswers / stats.totalAttempted) * 100)
                    : 0;
                document.getElementById('accuracy').textContent = accuracy + '%';
                
                stats.totalTime = questionStates.reduce((acc, state) => acc + state.timeSpent, 0);
                const timeSpent = Math.floor(stats.totalTime / 1000);
                const minutes = Math.floor(timeSpent / 60);
                const seconds = timeSpent % 60;
                document.getElementById('timeSpent').textContent = 
                    minutes + ':' + seconds.toString().padStart(2, '0');
            }
        }

        function setupVideo(videoElement, url) {
            if (Hls.isSupported()) {
                const hls = new Hls();
                hls.loadSource(url);
                hls.attachMedia(videoElement);
            } else if (videoElement.canPlayType('application/vnd.apple.mpegurl')) {
                videoElement.src = url;
            }
        }

        function displayQuestion() {
            if (!questionsData || questionsData.length === 0) {
                document.getElementById('questionText').innerHTML = 'No questions available for this quiz.';
                return;
            };
            
            const question = questionsData[currentQuestionIndex];
            questionStartTime = Date.now();
            
            selectedOption = questionStates[currentQuestionIndex].selectedAnswer;
            
            const progress = ((currentQuestionIndex + 1) / questionsData.length) * 100;
            document.getElementById('progressBar').style.width = progress + '%';
            document.getElementById('currentQuestion').textContent = currentQuestionIndex + 1;
            updateQuestionNav();
            
            document.getElementById('prevBtn').disabled = currentQuestionIndex === 0;
            
            document.getElementById('solutionContainer').classList.add('hidden');
            
            document.getElementById('questionText').innerHTML = question.text || 'No question text available';
            
            let mediaHtml = '';
            if (question.question_audio) mediaHtml += `<div class="glass-light p-4 mb-4"><audio src="${question.question_audio}" controls class="w-full"></audio></div>`;
            if (question.question_video) mediaHtml += `<div class="glass-light p-4 mb-4"><video src="${question.question_video}" controls class="w-full rounded-lg"></video></div>`;
            if (question.question_images) {
                question.question_images.forEach(imgSrc => {
                    if (imgSrc) mediaHtml += `<div class="glass-light p-4 mb-4"><img src="${imgSrc}" alt="Question Image" class="w-full rounded-lg"></div>`;
                });
            }
            document.getElementById('questionMedia').innerHTML = mediaHtml;
            
            const optionsContainer = document.getElementById('optionsContainer');
            optionsContainer.innerHTML = '';
            optionsContainer.classList.remove('answered');
            
            if (question.choices && Array.isArray(question.choices)) {
                question.choices.forEach((choice, index) => {
                    const optionLetter = String.fromCharCode(65 + index);
                    const isSelected = selectedOption === index;
                    
                    const optionDiv = document.createElement('div');
                    optionDiv.innerHTML = `
                        <button type="button" class="option-button ${isSelected ? 'selected' : ''}" data-option-index="${index}">
                            <div class="option-letter">${optionLetter}</div>
                            <div class="option-text">${choice.text || 'Option ' + (index + 1)}</div>
                        </button>
                    `;
                    optionsContainer.appendChild(optionDiv);
                });
                
                optionsContainer.addEventListener('click', function(e) {
                    const optionButton = e.target.closest('.option-button');
                    if (optionButton) {
                        const optionIndex = parseInt(optionButton.getAttribute('data-option-index'));
                        selectOption(optionIndex);
                    }
                });
            }
            
            updateBookmarkButton();
            updateMarkReviewButton();

            if ((currentMode === 'timed_study' || currentMode === 'timed_exam') && !isQuizCompleted) {
                startTimer();
            }
        }

        function selectOption(index) {
            const optionsContainer = document.getElementById('optionsContainer');
            if (optionsContainer.classList.contains('answered')) return;

            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                questionStartTime = Date.now();
            }
            
            selectedOption = index;
            questionStates[currentQuestionIndex].selectedAnswer = index;
            
            document.querySelectorAll('.option-button').forEach((btn, i) => {
                btn.classList.toggle('selected', i === index);
            });
            
            if (currentMode === 'study' || currentMode === 'timed_study') {
                processAnswer();
            } else {
                if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                    questionStates[currentQuestionIndex].status = 'answered';
                    stats.totalAttempted++;
                    stats.notAttempted--;
                }
                updateQuestionNav();
            }
            saveProgress(); // NEW: Save on answer selection
        }

        function processAnswer() {
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            
            if(selectedOption === null) return;

            const selectedChoice = question.choices[selectedOption];
            const isCorrect = selectedChoice.id === correctChoiceId;
            
            if (questionStates[currentQuestionIndex].status === 'not_attempted') {
                stats.totalAttempted++;
                stats.notAttempted--;
                if(isCorrect) stats.correctAnswers++; else stats.incorrectAnswers++;
            }
            questionStates[currentQuestionIndex].status = isCorrect ? 'correct' : 'incorrect';
            
            updateStats();
            showInlineFeedback(isCorrect);
            updateQuestionNav();
        }

        function showInlineFeedback(isCorrect) {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;

            const optionsContainer = document.getElementById('optionsContainer');
            const optionButtons = optionsContainer.querySelectorAll('.option-button');
            const question = questionsData[currentQuestionIndex];
            const correctChoiceId = question.correct_choice_id;
            let correctOptionIndex = question.choices.findIndex(c => c.id === correctChoiceId);

            optionsContainer.classList.add('answered');

            optionButtons.forEach((btn, index) => {
                btn.classList.remove('selected');
                if (index === correctOptionIndex) btn.classList.add('correct');
                else if (index === selectedOption && !isCorrect) btn.classList.add('incorrect');
            });

            showSolution();
        }


        function showSolution() {
            if (currentMode !== 'study' && currentMode !== 'timed_study') return;
            
            const question = questionsData[currentQuestionIndex];
            document.getElementById('solutionText').innerHTML = question.solution || 'No solution provided';
            
            const videoContainer = document.getElementById('solutionVideo');
            const videoPlayer = document.getElementById('explanationVideoPlayer');
            const explanationVideo = question.explanation_video;
            
            if (explanationVideo) {
                videoContainer.classList.remove('hidden');
                if (explanationVideo.includes('.m3u8')) setupVideo(videoPlayer, explanationVideo);
                else videoPlayer.src = explanationVideo;
            } else {
                videoContainer.classList.add('hidden');
            }

            const audioContainer = document.getElementById('solutionAudio');
            audioContainer.innerHTML = '';
            if (question.explanation_audio_eng) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English Explanation:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
            }
            if (question.explanation_audio_hin) {
                audioContainer.innerHTML += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish Explanation:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;
            }
            
            const imagesContainer = document.getElementById('solutionImages');
            imagesContainer.innerHTML = '';
            if (question.explanation_images) {
                 question.explanation_images.forEach(imgSrc => {
                    if(imgSrc) imagesContainer.innerHTML += `<div class="mt-4"><img src="${imgSrc}" alt="Explanation Image" class="w-full rounded-lg"></div>`;
                });
            }

            document.getElementById('solutionContainer').classList.remove('hidden');
        }

        function submitQuiz() {
            if (timer) clearInterval(timer);
            if (!confirm('Are you sure you want to submit the quiz?')) return;
            
            isQuizCompleted = true;
            let correct = 0, incorrect = 0;
            const totalTime = Date.now() - quizStartTime;
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                if (state.selectedAnswer !== null) {
                    if (question.choices[state.selectedAnswer].id === question.correct_choice_id) {
                        correct++;
                        state.status = 'correct';
                    } else {
                        incorrect++;
                        state.status = 'incorrect';
                    }
                }
            });
            
            // Save performance data
            const performanceData = JSON.parse(localStorage.getItem('quizPerformanceData')) || [];
            performanceData.push({
                quizName: quizName,
                hierarchy: hierarchy,
                timestamp: Date.now(),
                totalTime: totalTime,
                stats: {
                    correct: correct,
                    incorrect: incorrect,
                    notAttempted: questionsData.length - (correct + incorrect)
                }
            });
            localStorage.setItem('quizPerformanceData', JSON.stringify(performanceData));

            stats.correctAnswers = correct; // Update global stats
            stats.incorrectAnswers = incorrect;
            markQuizAsCompleted(); // NEW: Mark quiz as complete in history
            showPerformanceAnalysis(correct, incorrect, questionsData.length - (correct + incorrect), totalTime);
        }

        function showPerformanceAnalysis(correct, incorrect, notAttempted, totalTime) {
            const modal = document.getElementById('performanceModal');
            const accuracy = (correct + incorrect) > 0 ? Math.round((correct / (correct + incorrect)) * 100) : 0;
            
            const circumference = 2 * Math.PI * 65;
            const scoreCircle = document.getElementById('scoreCircle');
            scoreCircle.style.strokeDasharray = `${circumference} ${circumference}`;
            scoreCircle.style.strokeDashoffset = circumference - (accuracy / 100) * circumference;
            
            document.getElementById('accuracyScore').textContent = `${accuracy}%`;
            document.getElementById('totalQuestionsResult').textContent = questionsData.length;
            document.getElementById('correctResult').textContent = correct;
            document.getElementById('incorrectResult').textContent = incorrect;
            document.getElementById('notAttemptedResult').textContent = notAttempted;
            
            const totalMinutes = Math.floor(totalTime / 60000);
            const totalSeconds = Math.floor((totalTime % 60000) / 1000);
            document.getElementById('totalTimeResult').textContent = `${totalMinutes}:${totalSeconds.toString().padStart(2, '0')}`;
            
            const avgTime = totalTime / questionsData.length;
            const avgMinutes = Math.floor(avgTime / 60000);
            const avgSeconds = Math.floor((avgTime % 60000) / 1000);
            document.getElementById('avgTimeResult').textContent = `${avgMinutes}:${avgSeconds.toString().padStart(2, '0')}`;
            
            modal.classList.remove('hidden');
        }

        function closePerformanceModal() { document.getElementById('performanceModal').classList.add('hidden'); }

        function reviewQuestions() {
            document.getElementById('questionReviewSection').classList.remove('hidden');
            const container = document.getElementById('reviewQuestionsContainer');
            container.innerHTML = '';
            
            questionsData.forEach((question, index) => {
                const state = questionStates[index];
                const correctChoiceId = question.correct_choice_id;
                
                let statusClass = 'not-attempted', statusText = 'Not Attempted';
                if (state.selectedAnswer !== null) {
                    const selectedChoice = question.choices[state.selectedAnswer];
                    if (selectedChoice.id === correctChoiceId) { statusClass = 'correct'; statusText = 'Correct'; }
                     else { statusClass = 'incorrect'; statusText = 'Incorrect'; }
                }
                
                const reviewDiv = document.createElement('div');
                reviewDiv.className = `review-question ${statusClass}`;
                
                let optionsHtml = (question.choices || []).map((choice, choiceIndex) => {
                    const isSelected = state.selectedAnswer === choiceIndex;
                    const isCorrect = choice.id === correctChoiceId;
                    let borderClass = 'border-gray-600';
                    if(isCorrect) borderClass = 'border-green-500';
                    else if(isSelected) borderClass = 'border-red-500';
                    
                    return `<div class="p-3 rounded-lg border ${borderClass}"><span class="font-bold mr-3">${String.fromCharCode(65 + choiceIndex)}</span><span>${choice.text}</span></div>`;
                }).join('');

                const videoHtml = question.explanation_video ? `<div class="mt-4"><video id="review-video-${index}" data-src="${question.explanation_video}" class="w-full rounded-lg" controls></video></div>` : '';
                
                let audioHtml = '';
                if(question.explanation_audio_eng) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">English:</p><audio src="${question.explanation_audio_eng}" controls class="w-full"></audio></div>`;
                if(question.explanation_audio_hin) audioHtml += `<div class="mt-2"><p class="text-sm text-white text-opacity-70 mb-1">Hinglish:</p><audio src="${question.explanation_audio_hin}" controls class="w-full"></audio></div>`;

                let imagesHtml = (question.explanation_images || []).map(src => src ? `<div class="mt-4"><img src="${src}" alt="Explanation Image" class="w-full rounded-lg"></div>` : '').join('');

                reviewDiv.innerHTML = `
                    <div class="mb-4">
                        <div class="flex justify-between items-center mb-3">
                            <h4 class="text-lg font-bold text-white">Question ${index + 1}</h4>
                            <span class="text-sm px-3 py-1 rounded-full bg-${statusClass === 'correct' ? 'green' : statusClass === 'incorrect' ? 'red' : 'gray'}-600 text-white">${statusText}</span>
                        </div>
                        <div class="text-white mb-4">${question.text}</div>
                    </div>
                    <div class="space-y-2 mb-4">${optionsHtml}</div>
                    <div class="bg-green-900 bg-opacity-20 p-4 rounded-lg border border-green-700">
                        <h5 class="text-green-400 font-bold mb-2">Explanation:</h5>
                        <div class="text-white text-opacity-90">${question.solution || 'No solution available.'}</div>
                        ${videoHtml}
                        ${audioHtml}
                        ${imagesHtml}
                    </div>`;
                container.appendChild(reviewDiv);
            });
            initializeReviewVideos();
        }

        function initializeReviewVideos() {
            document.querySelectorAll('video[data-src]').forEach(videoEl => {
                const src = videoEl.dataset.src;
                if (src && src.includes('.m3u8')) {
                    setupVideo(videoEl, src);
                } else if (src) {
                    videoEl.src = src;
                }
            });
        }

        function retakeQuiz() {
            if (confirm('Are you sure you want to retake the quiz? This will reset all your answers.')) {
                if (window.location.pathname.endsWith('custom_quiz.html')) {
                    localStorage.removeItem('customQuizData');
                }
                clearProgress(); // NEW: Clear history on retake
                location.reload();
            }
        }

        function loadBookmarkedQuestions() {
            const bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            bookmarks.forEach(bookmark => {
                if (bookmark.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-'))) {
                    if (bookmark.questionIndex < questionsData.length) {
                        questionStates[bookmark.questionIndex].bookmarked = true;
                    }
                }
            });
        }

        function toggleBookmark() {
            const isBookmarked = !questionStates[currentQuestionIndex].bookmarked;
            questionStates[currentQuestionIndex].bookmarked = isBookmarked;
            
            let bookmarks = JSON.parse(localStorage.getItem('bookmarkedQuestions')) || [];
            
            if (isBookmarked) {
                const bookmarkData = {
                    quizName: quizName,
                    quizFile: window.location.pathname.split('/').pop(),
                    questionIndex: currentQuestionIndex,
                    question: questionsData[currentQuestionIndex],
                    hierarchy: hierarchy,
                    timestamp: Date.now()
                };
                bookmarks.push(bookmarkData);
            } else {
                bookmarks = bookmarks.filter(b => 
                    !(b.quizFile.includes(quizName.toLowerCase().replace(/ /g, '-')) && b.questionIndex === currentQuestionIndex)
                );
            }
            
            localStorage.setItem('bookmarkedQuestions', JSON.stringify(bookmarks));
            updateBookmarkButton();
            updateQuestionNav();
        }

        function updateBookmarkButton() {
            const btn = document.getElementById('bookmarkBtn');
            const text = document.getElementById('bookmarkText');
            const isBookmarked = questionStates[currentQuestionIndex].bookmarked;
            
            btn.className = isBookmarked ? 'gradient-yellow px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-yellow-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isBookmarked ? 'Bookmarked' : 'Bookmark';
        }
        
        function toggleMarkForReview() {
            questionStates[currentQuestionIndex].markedForReview = !questionStates[currentQuestionIndex].markedForReview;
            updateMarkReviewButton();
            updateQuestionNav();
        }

        function updateMarkReviewButton() {
            const btn = document.getElementById('markReviewBtn');
            const text = document.getElementById('markReviewText');
            const isMarked = questionStates[currentQuestionIndex].markedForReview;
            
            btn.className = isMarked ? 'gradient-purple px-6 py-3 text-white transition-all duration-300 flex items-center' : 'glass-light px-6 py-3 text-white hover:bg-purple-500 hover:bg-opacity-20 transition-all duration-300 flex items-center';
            text.textContent = isMarked ? 'Marked' : 'Mark for Review';
        }

        function previousQuestion() {
            if (currentQuestionIndex > 0) {
                if (questionStartTime) {
                    questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
                }
                
                currentQuestionIndex--;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            }
        }

        function nextQuestion() {
            if (questionStartTime) {
                questionStates[currentQuestionIndex].timeSpent += Date.now() - questionStartTime;
            }
            
            if (currentQuestionIndex < questionsData.length - 1) {
                currentQuestionIndex++;
                displayQuestion();
                saveProgress(); // NEW: Save on navigation
            } else {
                if (currentMode === 'test' || currentMode === 'timed_exam') {
                    if (confirm('You have reached the end of the quiz. Would you like to submit your answers now?')) {
                        submitQuiz();
                    }
                } else {
                    if (confirm('You have completed all questions. Would you like to review from the beginning?')) {
                        currentQuestionIndex = 0;
                        displayQuestion();
                        saveProgress();
                    }
                }
            }
        }

        function startTimer() {
            if (timer) clearInterval(timer);
            timeRemaining = 120; // 2 minutes per question
            updateTimerDisplay();
            
            timer = setInterval(() => {
                timeRemaining--;
                updateTimerDisplay();
                
                if (timeRemaining <= 0) {
                    clearInterval(timer);
                    if (currentMode === 'timed_exam') {
                        submitQuiz();
                    } else {
                        nextQuestion();
                    }
                }
            }, 1000);
        }

        function updateTimerDisplay() {
            const minutes = Math.floor(timeRemaining / 60);
            const seconds = timeRemaining % 60;
            document.getElementById('timeDisplay').textContent = 
                minutes + ':' + seconds.toString().padStart(2, '0');
        }

        function toggleSidebar() {
            document.getElementById('quizSidebar').classList.toggle('open');
        }

        document.addEventListener('DOMContentLoaded', () => {
             if (resume) {
                if (loadProgress()) {
                    document.getElementById('modeModal').style.display = 'none';
                    initializeQuiz(); // Resume directly into the saved mode and state
                } else {
                    // If resume fails (e.g., cleared history), start fresh
                    clearProgress();
                    document.getElementById('modeModal').style.display = 'flex';
                }
             } else if (!window.location.pathname.endsWith('custom_quiz.html')) {
                clearProgress(); // Clear old progress if not resuming
                document.getElementById('modeModal').style.display = 'flex';
             } else {
                initializeQuiz();
             }
        });
        
        document.addEventListener('keydown', function(e) {
            if (document.getElementById('modeModal').style.display !== 'none') return;
            if (document.getElementById('performanceModal').classList.contains('hidden') === false) return;
            
            if (e.key >= '1' && e.key <= '4') {
                const optionIndex = parseInt(e.key) - 1;
                const options = document.querySelectorAll('.option-button');
                if (optionIndex < options.length) selectOption(optionIndex);
            } else if (e.key === 'ArrowLeft') {
                previousQuestion();
            } else if (e.key === 'ArrowRight' || e.key === ' ') {
                e.preventDefault();
                nextQuestion();
            } else if (e.key.toLowerCase() === 'b' && (currentMode === 'study' || currentMode === 'timed_study')) {
                toggleBookmark();
            } else if (e.key.toLowerCase() === 'm' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                toggleMarkForReview();
            } else if (e.key.toLowerCase() === 's' && (currentMode === 'test' || currentMode === 'timed_exam')) {
                submitQuiz();
            }
        });
    </script>
</body>
</html>